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PREFACE AND THESIS OUTLINE 
 
Traumatic spinal cord injury affects an estimated 500.000 people in the United States 
and Europe alone and between fifteen per million (Europe) and forty per million (North 
America) new cases are reported each year. Mechanical force at the time of injury results 
in immediate neural cell death, severing of axons, rupturing of blood vessels, and overall 
loss of tissue integrity. Injury-induced events including inflammatory responses and 
release of cytotoxic substances result in progressive neuronal and oligodendrocyte death, 
demyelination, and axonal damage. Secondary injury contributes significantly to the 
pathology of spinal cord injury. The formation of scar tissue and, ultimately, a fluid-filled 
cyst, and the presence of axonal growth-inhibitory factors, create a chronically hostile 
environment for repair at and around the injury epicenter. As a result, spontaneous repair 
of anatomical damage and functional improvement after spinal cord injury is poor. 
Therapeutic interventions so far have had limited success resulting in a steadily growing 
group of people with paralysis due to spinal cord injury. The lifetime costs for care for a 
spinal cord injured person vary between one and three million dollars, making it one of 
the most expensive conditions to treat. The personal and societal consequences drive the 
research for treatments for spinal cord injury. 
Current research on spinal cord repair-promoting approaches uses animal models and 
focuses on neuroprotection, to limit secondary tissue loss; axonal regeneration, to 
promote growth and synaptogenesis of damaged axons; and plasticity, to recruit newly 
grown and/or spared axons into axonal circuitries involved in motor and sensory function. 
Over the last decades, the potential of cell transplantation as a reparative approach for 
the injured spinal cord has become evident in animal models. Transplanted cells may 
secrete trophic factors that exert paracrine effects that limit secondary injury, promote 
axonal regeneration and/or plasticity, or serve as a substrate for regenerating axons. 
Alternatively, cell transplants may be a source for replacement of lost and damaged neural 
cells. The mesenchymal stem cell-like bone marrow stromal cell (BMSC) is among the cell 
types that have been explored for spinal cord repair. BMSCs were shown to elicit 
anatomical repair accompanied by improved, but still partial, recovery of function. At 
10 
present, our understanding of the extent of the repair potential of intraspinal BMSC 
transplants and their underlying mechanisms is incomplete. This thesis has two main 
goals: (1) to expand our knowledge of BMSC therapy for spinal cord repair, and (2) to 
investigate approaches to enhance the therapeutic efficacy of intraspinal BMSC 
transplants. In the studies an adult rat model of spinal cord contusion was employed 
because a contusion is the most prevalent mechanism of spinal cord injury in humans.  
A comprehensive overview of the repair potential of stem cells for central nervous 
system repair and of BMSCs for spinal cord repair is provided in Chapter 1. In part A of 
chapter 1, stem cell terminology and experimental and clinical studies on stem cells for 
central nervous system repair will be discussed. In part B of Chapter 1, the advantages and 
disadvantages of using BMSCs as cell therapy for spinal cord repair are discussed. In 
addition, the spinal cord contusion model will be described in detail. To expand our 
knowledge of BMSC therapy for spinal cord repair, we focused on functional recovery and 
anatomical correlates thereof (Chapter 2) and the role of brain-derived neurotrophic 
factor (BDNF) in BMSC-mediated anatomical repair (Chapter 3). Comprehensive 
behavioral analyses were used to measure the effects of BMSC transplants on motor, 
sensorimotor, and sensory function recovery after BMSC transplantation into the adult rat 
contused spinal cord. Gene therapy was used to manipulate BDNF production in 
transplanted BMSCs to determine its involvement in BMSC-mediated repair. To enhance 
the therapeutic efficacy of BMSC transplants, we focused on BMSC survival in the injured 
spinal cord. The effect of reduced macrophage presence at the injury (transplant) site on 
BMSC survival was investigated by using clinically relevant anti-inflammatory drugs 
(Chapter 4). Whether increased survival enhances the effect of BMSC transplants on 
repair of the contused spinal cord is described in Chapter 5. A reverse thermal gel, 
poly(ethylene glycol)poly(serinol hexamethylene urethane) or ESHU with anti-oxidant 
properties was used to increase BMSC transplant survival and so prolong their presence in 
the injured spinal cord. In chapter 6 the findings of our studies and future directions will 















Introduction Part A 
 
 
Stem Cells for Central Nervous System Repair and 
Rehabilitation 
 





















The central nervous system (CNS) has limited capacity for self-repair. Current treatments 
are often incapable of reversing the debilitating effects of CNS diseases that result in 
permanent and/or progressive physical and cognitive impairments. One promising repair 
strategy is transplantation of stem cells, which can potentially replace lost neurons and/or 
glia or promote repair through secretion of trophic factors. Various types of stem cells 
exist, each with their own advantages and disadvantages. Although no consensus exists 
regarding the optimal cell type to use, moderate functional improvements have been 
shown in animal models of CNS diseases using different types of stem cells. However, the 
precise mechanism of action behind their beneficial effects remains unknown. In addition, 
many barriers to clinical use still need to be resolved before transplantation of stem cells 
can be used as effective biologics. These barriers include—depending on the stem cell 
type—possible tumor formation, difficulty with harvest, limited in vivo differentiation and 




Central nervous system (CNS) diseases are often characterized by complex immune-
mediated cytotoxic and apoptotic processes that result in the loss of function and 
permanent loss of neural cells
1
. Although many CNS diseases result from a loss of viable 
cells, a therapeutic approach must consider the type of cell lost to have a beneficial 
outcome. For example, Parkinson disease requires replacement of lost dopaminergic 
substantia nigra neurons, whereas multiple sclerosis requires reconstitution of functional 
oligodendrocytes. Stem cells have the potential to address this demand for specific cells 
for specific diseases because of their multipotency, and thus stem cell therapy is a 
promising biologic therapy to consider for persons with CNS diseases. 
 
In the past decade an explosive amount of stem cell research has been conducted, 
resulting in an insightful scope of knowledge on stem cell biology. Continuing research will 
be essential before effective bedside treatments for CNS diseases may be developed. This 
review aims to provide a critical overview of stem cell use for repair of CNS diseases 
relevant for rehabilitation medicine. 
 
DEFINITION, ORIGIN, AND VARIOUS TYPES OF STEM CELLS 
By definition, a stem cell is capable of self-renewal and of differentiating into at least one 
other cell type. The zygote is referred to as a totipotent stem cell. The blastocyst contains 
an inner cell mass consisting of self-replicating cells that can become all but trophoblast 
cells (the outer layer blastocyst cells that later become the placenta); these cells are 
known as pluripotent stem cells (Figure 1). When these cells enter into 1 of the 3 primary 
germ layers—ectoderm, mesoderm, or endoderm—they are referred to as multipotent 
stem cells. These cells then can become precursor cells, which are unipotent cells that 
differentiate into the final cell types within differentiated tissues (Figure 1). 
 
When stem cells are harvested from embryonic tissue, they are considered embryonic 
stem cells (ESC). When stem cells are taken from tissues from the adult body, they are 
16 
referred to as adult stem cells (ASC [note: adipose tissue-derived stem cells are sometimes 
also referred to as ASC]) or somatic stem cells. The existence of ASC was first 
demonstrated within the adult hematopoietic system, which throughout natural life gives 
rise to new blood cells
2
. After this discovery, ASC were demonstrated within numerous 
other adult tissues such as neural stem cells (NSC) in the brain, epidermal neural crest 
stem cells (EPI-NCSC) in hair follicles, muscle-derived (mesenchymal) stem cells in muscles, 
and bone marrow stromal cells (BMSC) in bone marrow. The functions of ASC are poorly 
understood, but one rational possibility would be that ASC support repair of the tissues in 
which they reside. At present, however, this theory has not been confirmed unequivocally, 
and it certainly does not appear to be the case in the CNS, where endogenous restoration 
is poor and disease or trauma typically elicits permanent damage. 
 
Fig. 1. Hierarchy of stem cells. Totipotent cells can develop into all cell types of the body, pluripotent cells can 
become all but trophoblast cells, multipotent cells can give rise to all cells within 1 of the 3 germ layers, and 
precursor cells are unipotent cells that will become terminally differentiated cells of specialized tissue. Ecto = 
ectoderm germ layer; meso = mesoderm germ layer; endo = endoderm germ layer. 
 
Recently, a third type of stem cell has emerged—the induced pluripotent stem (iPS) cell, 




The iPS cell is generated from an adult 
somatic cell by introducing transcriptional factors whose ectopic expression reprograms 
the cell into a pluripotent cell. The groundbreaking discovery ‘that mature cells can be 
reprogrammed to become pluripotent’ has earned Yamanaka the Nobel Prize in 
17 
Physiology or Medicine 2012. The prize was shared with John B. Gurdon who in 1962 used 
an enucleated oocyte into which the nucleus of an adult cell was transferred to create a 
stem cell capable of forming a blastula and eventually a tadpole
4
. In June 2013 the somatic 
cell nuclear transfer method was for the first time successfully used for human embryonic 
stem cell generation
5
. The discovery of generated stem cells is opening exciting new 




UTILITY OF NEURAL AND NON-NEURAL STEM CELLS 
NSC can contribute in different ways to repair of the brain and spinal cord. They can 
potentially differentiate into neurons and/or glial cells and replace those that were lost as 
a result of the disease or trauma. Alternatively, NSC can serve as vectors for growth 
factors that could support cell survival, cell proliferation, axon regeneration, and blood 
vessel formation, which can all positively influence CNS repair. It is also possible that stem 
cells serve as a substrate for regenerating axons and thus contribute to repair. Thus far, 
numerous studies have demonstrated the potential of stem cells for CNS repair. 
Interestingly, the mechanisms underlying their benefits remain elusive. 
 
Embryonic NSC have a robust capacity to differentiate into neural cells and are therefore 
suitable for repair strategies based on cell replacement. However, their impressive 
differentiation capacity comes with uninhibited proliferation, which could result in tumor 
formation after transplantation. This factor, together with ethical concerns surrounding 
their harvest, has limited the application of ESC for CNS repair. Adult NSC also are capable, 
albeit less so than ESC, of differentiating into neural cells, and in contrast to ESC, they are 
not known for causing tumors after transplantation. Thus adult NSC are good candidate 
cells for neural replacement approaches. A disadvantage of adult NSC is that they are 
difficult to obtain because they need to be harvested from the adult brain or spinal cord. 
 
Compared with embryonic and adult NSC, non-neural stem cells are more readily 
obtainable. For instance, BMSC reside in bone marrow, EPI-NCSC in hair follicles, and 
muscle-derived (mesenchymal) stem cells in muscles, and all these tissues are relatively 
18 
easy to harvest from adults. Some of these non-neural stem cells offer additional 
advantages such as the low expression of major histocompatibility complex I molecules by 
BMSC that would help evade immunologic rejection. Importantly, it was reported that 
several types of non-neural stem cells could (trans)differentiate into neural cells
7
, which 
has opened new avenues for CNS repair. However, at present, this potential to become a 
neuron, astrocyte, or oligodendroglial cell has not been unambiguously proven and is in 
fact a subject of controversy. If this ability to transdifferentiate into neural cells is low or 
absent, their benefits in replacement strategies would be poor. On the other hand, non-
neural stem cells may offer effective means to repair the CNS through their ability to 
secrete repair-supporting molecules such as growth factors. Moreover, in accordance with 
their decreased differentiation capacity, these cells are less inclined to unrestrained 
proliferation and are therefore less tumorigenic. Table 1 provides an overview of the 
relative advantages and disadvantages of different types of stem cells. The current 
controversies and challenges within the field of regenerative medicine are best illustrated 
with the following example. For a mesodermally derived BMSC to be suitable for CNS 
repair based on cell replacement, it will need to transdifferentiate into a neuron or neural 
glial cell. For this transdifferentiation to occur, the BMSC will first need to revert into a 
pluripotent cell, subsequently differentiate into an ectodermal precursor cell, and 
 
Table 1. Relative advantages and disadvantages of embryonic and adult stem cells for human use 
in CNS disease 
 ESC ASC iPS 





Good Poor Good 
Harvest Controversial Difficult Easy Easy 
Tumorigenicity High Low Low High 
Abbreviations: ESC, embryonic stem cell; ASC, adult stem cell; NSC, neural stem cell; MSC, mesenchymal stem 
cell; iPS, induced pluripotent stem cell 
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then differentiate into a neuron, astrocyte, or oligodendrocyte. Several studies have 
shown that BMSC can be induced in vitro to express neuronal markers and even to have 
some electrical neuronal properties, but true transdifferentiation into a fully functioning 
neuron is strongly debated
8
. Similarly, a few in vivo studies
7,9
  have shown expression of 
neuronal markers and/or anatomic integration after transplantation of BMSC, but 
neuronal functionality (ie, synapse formation, firing of action potentials, and release of 
neurotransmitters) or glial functionality has not been shown unequivocally. For example, 
Kopen and colleagues (1999)
7
 reported the expression of glial fibrillary acidic protein, a 
marker for astrocytes, in BMSC after transplantation into mice brain ventricles and 
concluded that they had transdifferentiated into mature astrocytes. The expression of 
specific neural markers is an important first step toward applying BMSC for CNS cell 
replacement, but it appears to be a rare event, and it is not a demonstration that the cell 
has become a functional component of the nervous system. 
 
ANATOMIC AND FUNCTIONAL REPAIR AFTER STEM CELL TRANSPLANTATION IN ANIMAL 
MODELS OF CNS DISEASE 
In the past decade a number of studies showed that transplantation of NSC can result in 
histologic and/or functional improvements in rodent models of various CNS diseases. 
Cummings and colleagues
10
 demonstrated remyelination of axons and functional 
improvements after transplantation of NSC into a mouse spinal cord injury model. 
Improved motor function was observed in hemiplegic mice after implantation of monkey 
ESC
11
. Table 2 provides a selected overview of studies that have transplanted neural and 
non-neural stem cells in different CNS disease models and reported repair. Typically, in 
ESC transplantation paradigms, some degree of differentiation into neurons and glia is 
shown. From the results it appears that NSC preferentially differentiate into astrocytes. 
Some may also differentiate into oligodendrocytes, but very few differentiate into 
neurons. Whether these newly generated neural cells then integrate within the host CNS 
tissue is not always clearly demonstrated. Despite the alleged in vitro ability, it is not often 
reported that non-neural stem cells become neural cells after transplantation into the 




 showed improvements in sensory connectivity and in touch perception after 
transplantation of EPI-NCSC in a mouse spinal cord injury model. In this study it was 
proposed that the neural crest cell–derived EPI-NCSC have the advantages of ESC and ASC 
because they are able to differentiate into oligodendrocytes and neuroblasts without 
being tumorigenic and are easily obtained from the bulge of hair follicles. 
 
Table 2. Selected overview of studies that have implanted stem cells in rodent models of spinal 
cord injury, stroke or Parkinson’s disease 
Type of 
stem cell 
Disease Model Differentiation Functional 
Outcome 
Reference 
ESC SCI, rat Astrocytes, oligo’s, 
neurons 
↑BBB McDonald et 
al.
36 
Fetal NPC SCI, rat Neurons ↑Pellet retrieval Ogawa et al.
37 
BMSC SCI, rat -  ↑BBB Hofstetter et al. 
2002
21 



























NSC Stroke, rat Neurons, astrocytes - Kelly et al.
38 




Abbreviations: ESC, embryonic stem cell; SCI, spinal cord injury; oligo’s, oligodendrocytes; BBB, Basso, Beattie, 
and Brasnahan-scale; NPC, neural progenitor cell; BMSC, bone marrow stromal cell; NSC, neural stem cell; EPI-
NCSC, epidermal neural crest stem cells; iPS, induced pluripotent stem cell. 
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Another cell type that has putative neural differentiation capacity without being 
tumorigenic is the iPS cell. The therapeutic potential of iPS cells was nicely demonstrated 
in a mouse spinal cord injury model, which revealed that transplanted iPS cell–derived 
neurospheres differentiated into all 3 neural cell types, participated in remyelination, 
promoted axonal outgrowth, and improved locomotor function
13
. Additionally, this study 
circumvented tumor formation by pre-evaluation and selection of the neurospheres for 
tumorigenicity
13
. This study was partially confirmed by Nutt and colleagues, who showed 
successful transplantation and integration of iPS cell-derive NPCs into an early chronic 
spinal cord injury model, however, without evidence of functional improvement.
14 
 
IMPROVING THE OUTCOME AFTER STEM CELL TRANSPLANTATION INTO THE DAMAGED 
CNS 
Notwithstanding recent reports that transplanted stem cells can become neural cells, the 
key mechanism for functional improvements observed after ASC transplantation in the 
CNS is thought to be neuroprotection, that is, limiting the loss of tissue. Neuroprotection 
can be accomplished through the secretion of growth factors, such as brain-derived 
neurotrophic factor, glial cell line–derived neurotrophic factor, and nerve growth factor. A 
cell transplant provides long-term delivery of growth factors, which is an important 
advantage over direct injection, because growth factors dilute rapidly and typically have 
short half-lives. For this reason, recent studies have genetically engineered stem cells to 
overexpress such growth factors, with the aim of enhancing their neuroprotective capacity 
and, as a result, their repair-supporting potential. Wu and colleagues
15
 showed a 
neuroprotective effect of glial cell line–derived neurotrophic factor-overexpressing BMSC 
in a Parkinson model. Axonal regeneration and enhanced functional recovery was found 





The beneficial effects of stem cells can also be increased by pre-differentiating the cells in 
vitro prior to transplantation. This pre-differentiation can be achieved by growing the cells 




 showed improved axon regeneration and locomotor function in 
rats with spinal cord injuries after transplantation of astrocytes differentiated from 
embryonic glial-restricted precursors, but not undifferentiated glial-restricted precursors. 
Hofstetter and co-workers
18
 transduced NSC with neurogenin-2 to suppress astrocytic 
differentiation prior to transplantation into rats with spinal cord injuries and 
demonstrated prevention of graft-induced sprouting, decreased allodynia, and improved 
functional recovery. Although these 2 studies achieved some degree of restoration with 
use of opposite differentiation protocols, it is clear that both demonstrated that the 
repair-supporting abilities of stem cells can be positively influenced prior to 
transplantation. 
 
Another way to improve the outcome is by combining stem cell transplantation with 
putative additive or synergistic treatments. Even though combinatorial strategies are 
thought to be essential to achieve biologically significant repair, exploration of these 
strategies has been sparse. Combining BMSC transplantation with an inhibitor of Rho-
kinase
19
, a molecule known to prevent neurite outgrowth, or with olfactory ensheathing 
cells
20
, another adult cell type that has been shown to benefit anatomic and functional 
CNS repair, did not improve functional outcomes in rats with spinal cord injuries more 
than BMSC transplantation alone. In a similar model, the combination of BMSC with 
physical exercise did not improve function compared with control subjects
21
. On the other 
hand, in both a spinal cord injury
22
 and a stroke
23
 model, the outcome after 
transplantation of brain-derived adult NSC with olfactory ensheathing cells was improved 
compared with transplantation of each of the cell types alone. In a rat model of cerebral 
ischemia, the combination of BMSC with erythropoietin showed a synergistic effect on 
neurogenesis and memory performance but not on locomotor function
24
. Because of our 
limited current knowledge about mechanisms underlying single treatments, it is difficult to 
select the appropriate combinations in which the single interventions would exert additive 
or synergistic effects. Future elucidation of mechanisms will allow more rationally targeted 
combinatorial repair strategies. 
23 
It is clear that, despite some promising results, stem cell–based repair of the damaged 
CNS still has major challenges to overcome before it can be successfully applied in a 
clinical setting. These challenges vary between tumorigenic and ethical concerns with 
ESC
25
, differentiation issues with ASC
26,27
, and survival of transplanted stem cells in 
general
28
. Poor survival of stem cells after injection into damaged CNS tissue can be due to 
poor vascularization of the transplantation site or a result of inflammation with 
accompanying secretion of cytotoxic molecules and rejection by activated immune cells. 
To optimally benefit from transplanted stem cells, it will be necessary to develop 
strategies to improve survival of the cells after transplantation. Although concomitant 
treatment with immunosuppressive drugs
27
, improving the timing of cell transplantation
28
, 
and transplantation of cells within a scaffold all have been shown to benefit cell survival, 
the majority of cells still die within weeks of transplantation. Clearly, further studies that 




Despite our incomplete knowledge, several clinical trials are currently being conducted in 
which stem cells are being transplanted in patients with Parkinson disease, stroke and 
other neurological disorders, with variable results thus far. After transplantation of human 
fetal mesencephalic tissue in patients with Parkinson disease, grafted neurons have been 
reported to survive and integrate, with improvements in several outcome parameters. 
These improved parameters included a 37% reduction in Levodopa dose, a 40% 
improvement in 18F-Flurodopa uptake (a measurement of dopaminergic activity in the 
putamen), a 44% improvement in the Unified Parkinson Disease Rating Scale Motor Score 
(while being off medication), a 39% decrease in “off medication” time, and a 49% decrease 
in “on medication” time with dyskinesia, according to a meta-analysis
29
. 
Impressively, up to sixteen years after transplantation, dopaminergic innervations in basal 
ganglia could be restored to normal levels and was associated with relief of motor 
symptoms.
30 
Variability across studies, however, is high. The differences between the 
observations in different clinical trials are likely due to variances in recipient 
24 
characteristics (eg, younger patients seem to show better recovery after neural grafting), 
the use of different surgical techniques, and/or (lack of) immunosuppressive drug 
administration, resulting in decreased graft survival.  
 
The first clinical trial using human ESC for spinal cord injury was approved in 2009 by the 
United States Food and Drug Administration (FDA). In this Phase I trial, oligodendrocyte 
progenitor cells derived from human ESCs were safely transplanted into five severe spinal 
cord injury patients. In November 2011 however, the trial was discontinued for financial 
reasons.
31
 Another Phase I/II trial by StemCells Inc using human CNS stem cells for spinal 
cord injury is currently underway in Switzerland and Canada and has recently (October 
2013) been approved by the FDA
32
. Small clinical trials in other neurologic diseases, 
including stroke
33
 and Huntington disease
34
, seem to support the potential use of stem 
cells, because moderate functional improvements are being achieved in some patients. 
For example, after transplantation of neuronal cells in 12 patients who have sustained a 
basal ganglia stroke, 6 patients showed improvements on the European stroke scale (a 
gain of 3 to 10 points) 12 to 18 months after transplantation
33
. Transplantation of fetal 
neural tissue in 5 patients with Huntington disease resulted in cognitive improvements in 
3 patients the first 2 years after surgery, which then faded after 4-6 years, as measured by 
the Unified Huntington Disease Rating Scale and neuropsychological tests. Safety was 
shown up to ten years postoperatively
35
. Several other clinical trials are in or have 
completed phase I/II of safety, but large trials of efficacy of stem cells for neurological 
disorders are still lacking. 
 
CONCLUSION 
Transplantation of stem cells can potentially be used for treatment of various CNS 
diseases. Progress is being made in the laboratory, and in various animal models of CNS 
disease/disorders, moderate functional improvements are being reported. The underlying 
mechanisms are still mostly unclear. In addition, determination of which stem cell type 
would be best for a particular CNS disease/disorder is still largely unresolved. Clearly many 
issues need to be elucidated before safe and effective stem cell-based therapies can be 
25 
designed for bedside treatments of neurologic disorders. All these issues warrant further 
investigations before stem cells can live up to their potential as effective biologic 
treatments for CNS disease. 
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In 1927 Harvey Cushing described the outcome for soldiers with
 
spinal cord injury (SCI) 
sustained during World War I: "Fully 80
 
percent died in the first few weeks in consequence 
of infection
 
from bedsores and catheterization. Only those cases survived
 
in which the 




this has been reversed. In well-
organized
 
systems of care for trauma and SCI and due to improved critical-care medicine 
most patients survive the initial hospitalization. At present, there is no treatment available 
that effectively re-establishes disrupted axonal circuitries that are necessary to restore 
injury-induced functional deficits. Due to the lack of a cure and the improved health care, 
the number of wheelchair bound people increases steadily each year. Currently, in the 
United States there are an estimated 400,000 people with SCI, with an
 
annual incidence of 
11,000 (The National Spinal Cord Injury Statistical Center, Birmingham, AL). In Western 
European countries similar leading causes of SCI are obtained as in the United States, with 
vehicular crashes and falls as leading causes of SCI and predominantly young males 
affected
2,3
. In contrast to the developed countries, in the less developed countries a shift 






Following the first medical care in a hospital, continuing medical care is necessary to 
maintain the SCI patient’s health and quality of life. This does not lead to functional repair. 
Repair-promoting pharmaceutical and/or surgical interventions will be necessary to 
significantly change the functional outcome after SCI. Transplantation of repair-supporting 
cells is considered a candidate repair approach. A bone marrow stromal cell (BMSC) 
transplant has shown great promise for spinal cord repair. This chapter will give an 
overview of the pathophysiology, clinical consequences, assessments, and treatments of 
SCI and will then focus on BMSC as a possible therapy for SCI. In addition, the SCI model 
system used in subsequent chapters will be explained. 
 
PATHOPHYSIOLOGY AND CLINICAL CONSEQENCES 
A direct force to the vertebral column can cause damage to bony and soft tissue 
structures. Torn ligaments or fractures can cause instability of the vertebral column with 
32 
potential risk of additional damage. Fracture dislocation and hematomas can directly 
compress the spinal cord and cause immediate neural cell death, axon damage and 
demyelination, resulting in instant loss of motor and sensory function. After the first 
destructive events, a sequence of molecular and cellular pathophysiological events, 
including an aggressive inflammatory response within the damaged tissue, leads to 
additional tissue loss at the injury epicenter and at distant sites (secondary injury)
8,9
. The 
functional consequences of SCI are highly variable and depend on the degree of tissue 
damage, which in turn depends on the impact severity. In patients with SCI with a 
relatively small amount of tissue damage, some endogenous recovery of function can be 
observed, which is most likely resulting from plasticity of the spinal nervous tissue
10,11
. In 
people with SCI with extensive tissue damage the neurological deficits are generally major 
and permanent. There are very few reports of people with a large injury that regain motor 
function to a degree that independence can be achieved.  
 
Over 95% of SCI patients survive their initial hospitalization. The relatively young age when 
SCI occurs, improved medical care, and lack of effective therapies are responsible for the 
continually increasing number of paralyzed people with SCI. This puts a high financial 
burden on the patient, his/her family, and society
3,12
. The psychological consequences of 
SCI should not be underestimated and appropriate guidance of patient and family should 
have an important place in the management of SCI
13-15
. Patients need time to accept their 
deficits. One can expect an initial period of denial and/or inability to fully comprehend the 
consequences of the paralysis caused by the injury. After the patient realizes his/her fate 
to the fullest extent, a period of acceptance will have to run its course
13
. After that, the 
patient needs to learn to live with his/her disabilities, and this may be accompanied by 





SCI is the second most expensive condition to treat in the United States after respiratory 
distress syndrome in infants and is ranked third in medical conditions requiring the longest 
stay in hospitals
16
. The costs of lifetime care for a SCI patient varies between 1 and 3 
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million dollars. The Center for Disease Control in the United States estimated that about 
10 billion dollars are spent yearly on SCI treatment excluding the management of pressure 





An acute and a chronic phase can be distinguished after SCI. Since SCI is often a 
consequence of severe accidents, initial treatment is generally focused on stabilization of 
the patient. There is insufficient evidence that would support standards of care during the 
acute phase of SCI. It is advised to maintain patients in an intensive care unit for close 
monitoring of respiratory and hemodynamic complications. For adequate spinal perfusion, 
which can be at risk due to injury-induced edema, a mean arterial pressure of 85-90 
mmHg should be maintained
18
. Depending on the type of injury, surgical interventions 
should be considered to decompress the spinal cord and or stabilize the spinal column
19,20
. 
Decompression surgeries may accelerate functional improvements and result in shorter 
hospitalization and rehabilitation periods
17,21
 . However, it does not result in an improved 
functional outcome
22
. A lack of consensus of care during the acute phase of SCI is in part 
due to the large variability among injuries and makes its early management complicated. If 
bone fragments continue to compress the spinal cord, early surgery may be vital to 
prevent exacerbation of spinal cord tissue destruction. However, in cases without a clear 
sign of such urgency there is no consensus on whether and what type of early 
surgical/clinical interventions must be implemented. The type of surgical intervention 
should be considered on a case-to-case basis, which makes it complicated to study the 
efficacy of intervention in the acute phase after SCI in randomized and controlled clinical 
trials.  
 
Besides surgical interventions, pharmacological treatments to limit the secondary injury 
after SCI are often considered. The best-known treatment is a high dose of the 
glucocorticosteroid, methylprednisolone sodium succinate (MPSS) within 8 hours after the 
injury
23-25
. Experimentally it was demonstrated that a high dose of MPSS reduces the 
inflammatory response and limit tissue loss after damage to the spinal cord. The effects of 
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MPSS in patients with SCI were investigated in 3 consecutive National Acute Spinal Cord 
Injury Studies (NASCIS)
23-25
. The results demonstrated that MPSS treatment in the acute 
phase of SCI resulted in neurological improvements up to 6 months after injury. After a 
thorough review of the results from the NASCIS studies and a more comprehensive 
assessment of the benefits and risks involved in high dose MPSS treatment, the 
therapeutic benefits are now disputed
26-28
. Especially in patients with complete SCI high 
dose steroid treatment can lead to adverse effects such as myopathy and wound infection 
that may negatively influence functional outcome and in some cases may be life-
threatening
28,29
. Currently, many SCI clinics worldwide have discontinued the ‘standard’ 
acute administration of MPSS after SCI.  
 
Treatment paradigms in the chronic stage after SCI are multidisciplinary and intensive. 
Different complications may occur that each demands specific interventions. For instance, 




, and autonomic dysreflexia with loss of 
bladder and bowel control
31
. It has to be taken into consideration that many SCI patients 
get accustomed to the specific injury-related pain they experience and as a result reveal 
their distress to their physician often at a late stage
32,33
. For some SCI-related conditions, 
such as decreased fertility, it is the patient’s personal desire that should guide the 
physician’s actions. Other common problems that arise after SCI are septicemia, 
respiratory insufficiency, and pneumonia due to muscle atrophy. These complications may 
cause clinical deterioration and could eventually result in death. They often occur without 
typical symptoms. It is imperative that SCI patients receive annual screenings and long-
term follow-ups to prevent these secondary complications. It is advised to treat patients 
on a regular basis with pneumococcal and influenza vaccine to prevent opportunistic 
infections. Monitoring the skin and urinary tract and implementing aggressive treatments 
against pressure ulcers and urinary tract infections is needed to reduce the risk of 
septicemia. Appropriate nutrition and exercise should also be incorporated in the (new) 






BONE MARROW STROMAL CELL THERAPY 
Mesenchymal stem cells from bone marrow (here referred to as bone marrow stromal 
cells (BMSCs)) have therapeutic potential for the injured spinal cord
35
. BMSC were shown 
to differentiate into bone, fat, tendon and cartilage cells
36
. Although still debated, it has 







, and neural cells
37,40
. Besides this ability, BMSC are also known to 
produce different types of growth factors that could potentially influence nervous tissue 
repair positively. Together, these abilities make BMSC interesting for repair strategies for 
the injured spinal cord.  
 
Several other aspects make BMSC interesting candidates for cell-based approaches for 
central nervous system repair. Firstly, BMSC are relatively easy to obtain from a fairly 
routine bone marrow extraction followed by a quick centrifuge and culture procedure to 
remove the hematopoietic cells. Secondly, BMSC are easy to culture as they do not need 
complicated growth media or special culture circumstances. Basic cell culture equipment 
is sufficient to successfully culture millions of BMSC.  Thirdly, BMSC are easy to transduce 
with viral vectors which, if necessary, may be helpful to boost the overall reparative 
abilities of the cells. The use of viral vectors to genetically modify cells prior to 
transplantation has not yet become mainstream as there are some biological and ethical 
issues that need to be resolved. Finally, BMSC do not have the ethical concerns that 
embryonic or fetal stem cells have, and therefore circumvent public rejection as a possible 
treatment for neural and non-neural trauma and disorders.  
 
At this time, there is no irrefutable evidence that BMSC transplanted into the damaged 
nervous tissue differentiate into neural cells that successfully replace lost cells. Also, there 
is no convincing evidence that neural cells derived from grafted BMSC contributed to 
functional improvements after transplantation. As long as the potential of BMSC for 
differentiation into neural cells is in debate, the ability to produce and secrete different 
types of growth-promoting molecules, which include several neurotrophins and cytokines, 
is the more interesting and more likely characteristic of BMSC that makes these cells 
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important candidates for spinal cord repair approaches. By releasing these molecules, 
BMSC can positively influence the consequences of spinal cord injury and support 
anatomical and functional repair (Figure 1). 
 
Fig. 1.  BMSC secrete various growth factors, including BDNF, VEGF, NGF and NT-3. These factors are thought to 
limit the loss of tissue in the injured spinal cord, contributing to the increased functional outcomes after BMSC 
transplantation. 
 
RAT MODEL SYSTEM 
Promising therapies for spinal cord injury are typically tested in rodent models, and mostly 
in rats. Similar as in humans, a SCI in the rat results in progressive loss of the grey and 
white matter creating large fluid filled cysts. Proliferation and activation of astrocytes 
result in formation of scar tissue, which acts as a barrier for axonal regeneration. 
Importantly, as in humans, there is no spontaneous regeneration in the injured spinal cord 
in rodents. The histological similarity between human and rat spinal cord injury has made 
the rat an extensively studied model for experimental therapeutic strategies, including 
BMSC transplantation.  
 
The most widely used model of spinal cord injury involves a spinal cord contusion inflicted 
by an impactor device. A contusion is clinically the most frequently occurring type of spinal 
37 
cord injury; approximately 75% of all human injuries are contusions. The consequences of 
a contusive injury in rats are similar as the known consequences in the contused human 
spinal cord. Figure 1 shows the rat model system for spinal cord contusive injury.  
 
An alternative model for a contusion-like spinal cord injury is the clip compression model. 
The main difference between the impactor-inflicted contusion and the clip-inflicted 
compression is time. With an impactor the spinal cord is compressed for a brief moment 
of time while with a clip the spinal cord is compressed for a longer, regulatable, time. The 
clip model is clinically more relevant as most spinal cord injuries are inflicted by a lasting 
compression rather than a brief one.   
 
There are a number of other, non-contusive, spinal cord injury models employed in 
laboratories around the world to test treatment paradigms. These are valuable in their 
own right to investigate the underlying mechanisms and/or validity of certain approaches. 
Partial transections of specific regions in the spinal cord are used especially to study the 
effects of treatments that aim to promote axonal regeneration; specific descending or 
ascending pathways can be damaged with relatively small local knife cuts and the 
regeneration response quantified at later time points. The involvement of specific axonal 
pathways in locomotor function can also be investigated using partial transections. The 
main disadvantages of partial transections are the low clinical relevance and the possible 
misinterpretation of results due to compensatory sprouting, i.e., other previously non-
involved axonal pathways become involved in particular functions. Another model that 
has been used is the complete transection of the spinal cord. Although this is not often 
seen in the clinic, complete transections are particularly advantageous to study cell types 
for their ability to promote regeneration of damaged axons without contaminating 
sprouting of undamaged pathways and to serve as bridging material between spinal cord 
stumps. This model is also suitable to study the efficacy of synthetic or natural 
biomaterials for their efficacy to serve as carrier of cells or drugs. A disadvantage besides 
the low clinical relevance is that rats with a completely transected spinal cord are more 
laborious to maintain. 
38 
 
Fig. 2. Rat spinal cord contusion model. A. A laminectomy is performed exposing the underlying spinal cord. B. 
Enlarged view of the exposed spinal cord segment. C. A computerized impactor is used to contuse the spinal 
cord. The piston is attached to a sensor to record velocity, force and displacement to ensure consistency. D. A 
moderate contusion results in loss of function at and below the level of injury and loss of bladder function. 
 
BMSC INJECTION 
It is difficult to provide standard guidelines for cell preparation because every cell type 
requires special conditions and circumstances for optimal isolation and culturing. Cell 
injection procedures may vary but are essentially similar. The standard procedures to 
harvest, culture and genetically modify BMSC with lentiviral vectors encoding for green 
fluorescent protein (GFP) to enable easy identification in vivo, as well as to inject BMSC as 
used in our laboratory are depicted in Figure 5. The length of the culture (preparation) 
time for BMSC depends on how many cells are needed to fill the damaged area. Thus, the 
number of BMSC necessary depends on the overall loss of tissue which, in turn, depends 
on the severity of the initial insult and on the time between insult and transplantation. 
Imaging techniques may provide the necessary information to guide the decisions on 
damaged tissue volumes and number of cells. 
 
There are a number of studies that have explored injection paradigms other than straight 
acute injections into the injury site. BMSC have been infused systemically or into the 4th 
ventricle
41
, or transplanted acutely into the cervical
42
 or thoracic spinal cord
43,44









Fig. 3. Transplantation of BMSC.  A. BMSC are isolated from femurs of rats by cutting off the epiphyses and 
flushing out the bone marrow. Cells are plated onto plastic culture dishes. Non-adherent hematopoietic stem 
cells are removed and the plastic-adherent BMSC are infected with LV-GFP. B. Cells are injected into the spinal 
cord contusion epicenter using a Hamilton syringe with a pulled glass needle attached, held within a 
micromanipulator.  C. Appearance of transplanted BMSC (green) in the contused rat spinal cord seven days post 
transplantation (20 μm thick section at 2.5 x magnification). The red color represents immunohistochemically 
stained glial fibrillary acidic protein (GFAP), a commonly used marker for astrocytes. 
 
TIMING OF TRANSPLANTATION  
In an experiment by Nandoe Tewarie and colleagues
46
 , BMSC were transplanted into a 
moderately contused adult rat spinal cord at 15 min, and at 3, 7, and 21 day post-injury 
and BMSC survival was closely assessed both during the transplantation procedure and up 
to four weeks after transplantation. In addition, the effect of the timing of BMSC 
transplantation on tissue sparing was determined. BMSC were collected from culture 
dishes, kept on ice, and passed through a glass pulled needle for injection into the 
contusion site. This procedure resulted in a majority (67 %) of the BMSC intended to be 
transplanted being present in the contusion at 15 min after transplantation. Thereafter, 
BMSC numbers rapidly decreased. The rate at which cell death occurs is different when 
transplanting acutely or delayed. In an acute transplantation paradigm (15 min post-
contusion) and sub-acute transplantation paradigm (3 days post-injury) BMSC survival is 
better than in a delayed transplantation paradigm (7 days or 21 days post-injury). The 
percentages of BMSC in the contusion at seven days after transplantation are 32% and 
52% for acute and sub-acute transplantation, respectively, and 9% for delayed 
transplantation. Four weeks after transplantation, almost no BMSC can be found in either 
paradigm (see figure 4). Interestingly, the presence of BMSC for this short period of time is 
sufficient to elicit tissue sparing. Acute and subacute transplantation, but not delayed 
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transplantation results in neuroprotection, and tissue volumes in these paradigms are 
strongly correlated with the number of BMSC present
46
. These results indicate that timing 
of BMSC transplantation is important for optimal survival and neuroprotective effect, with 
acute and subacute transplantation being superior to delayed transplantation. However, 
because of the clinical relevance of delayed treatment, it seems imperative to find 
strategies to improve BMSC survival in delayed paradigms. 
 
 
Fig. 4. A. BMSC numbers within a moderate contusion in the adult rat thoracic spinal cord decrease during 28 
days post-injection. The rate at which cell death occurs is higher when BMSC are transplanted 7 or 21 days post-
contusion, compared to BMSC transplantation 15 min or 3 days after contusion. B. The decreasing transplant is 
shown at 15 min (A–C), 7 days (D–F), and 28 days (G–I) after an injection at 15 min (acute), 7 days, and 21 days, 
respectively, post-injury. All microphotographs are from horizontal cryostat sections. (A) Scale bar, 600 mm in A–
I. 
 
Previously, using a rat contusion injury model, Hofstetter and colleagues
43
 showed that 
more BMSCs survived when transplanted one week after injury compared to immediately 
after injury. The surviving cells were located within trabeculae that span the injury site. 
These data are in disagreement with those from the Nandoe Tewarie study
46
 although 
long-term results were in agreement with only 1% of the cells (about 3000 total) surviving 
at 4 weeks after grafting.. The difference in early survival between the two studies may be 
that Hofstetter and co-workers injected the BMSC not only into the contusion but also 
rostral and caudal thereof into the spinal cord nervous tissue. Possibly, the surviving cells 
were located nearby but not in the contusion epicenter. Most studies have reported a 
poor survival of BMSC. Nandoe Tewarie and colleagues
46
 demonstrated that the contusion 
milieu is less detrimental during the first week after injury than the second and fourth 
41 
week after injury. What factors are important for BMSC survival in vivo? BMSCs are 
cultured in medium containing 10-20% serum. Factors other than present in serum are not 
essential for their survival and proliferation within the culture dish. In fact, addition of 
growth factors such as BDNF, FGF-2, or NT-3 instigates differentiation of the BMSCs into 
neural-like cells rather than affect survival. To date, the factors that may promote BMSC 
survival in vivo are unknown and further investigations are necessary to reveal them.  
 
CONCLUSION 
Stem cells have gained attraction over the last years in the field of neuroscience. In vitro it 
has been shown, although still disputed, that Bone Marrow Stromal Cells can 
transdifferentiate into cells of neural lineage. This has made this adult stem cell type 
interesting for neural transplantation paradigms. After transplantation of BMSC in the 
injured spinal cord most cells die. Nevertheless, especially in early transplantation, cells 
have a neuroprotective effect on the host tissue. This effect may well be the result of 
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Bone marrow stromal cell (BMSC) transplantation has shown promise for repair of the 
spinal cord. We showed earlier that a BMSC transplant limits the loss of spinal nervous 
tissue after a contusive injury. Here, we addressed the premise that BMSC-mediated 
tissue sparing underlies functional recovery in adult rats after a contusion of the thoracic 
spinal cord. Our results reveal that after two months BMSCs had elicited a significant 
increase in spared tissue volumes and in blood vessel density in the contusion epicenter. A 
strong functional relationship existed between spared tissue volumes and blood vessel 
density. BMSC-transplanted rats exhibited significant improvements in motor, 
sensorimotor, and sensory function which were strongly correlated with spared tissue 
volumes. Retrograde tracing revealed that rats with BMSCs had twice as many descending 
brainstem neurons with an axon projecting beyond the contused spinal cord segment and 
these correlated strongly with the improved motor/sensorimotor functions but not 
sensory functions. Together, our data indicate that tissue sparing greatly contributes to 
BMSC-mediated functional repair after spinal cord contusion. The preservation/formation 
of blood vessels and sparing/regeneration of descending brainstem axons may be 




Contusion of the adult rat thoracic spinal cord causes immediate locomotor and sensory 
impairments of the hindlimbs
e.g.,1,2
. Spontaneous recovery in locomotor ability reaches 
plateau levels a few weeks after a contusion
3-6
. Sensory function remains impaired
7,8
 with 
only small improvements months after trauma
9
.  
Transplantation of repair-promoting cells into the contused spinal cord has been explored 
as an intervention to restore function over what is spontaneously observed
e.g.,2,10-15
. Bone 
marrow stromal cells (BMSCs) are among the candidate cell types for spinal cord 
repair
14,16




BMSC transplantation into the contused rat spinal cord improves overground walking
20-29
. 
However, this particular gain in motor function was not observed in several other 
studies
30-33
. Little is known about the effects of BMSC transplants on contusion-induced 
sensory impairments. Himes and colleagues
23
 showed that BMSC transplantation into the 
contused adult rat spinal cord does not affect thermal hyperalgesia. 
The mechanisms underlying BMSC-mediated repair of the contused spinal cord remain 
elusive. Cell replacement is doubtful as grafted BMSCs survive poorly
e.g.,16,24,34
 and their 
differentiation into neural cells is moot
35-38
. Another possible repair mechanism is 
neuroprotection resulting in tissue sparing in the contused segment. Larger spared tissue 
volumes are often
e.g.,2,39-41
 but not always
42,43
 accompanied by improved functional 
outcome.  
In the present study, we tested the premise that BMSC-mediated tissue sparing underlies 
functional recovery in adult rats with a contused spinal cord. Previously, we showed that 
BMSC transplantation into the three-day old contused adult rat spinal cord elicits tissue 
sparing
34
. We employed this paradigm and investigated the contribution of tissue sparing 
in functional outcomes after two months. Moreover, blood vessel formation and 
descending brainstem axon sparing/regeneration were explored for their role in tissue 
sparing and functional restoration.  
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MATERIALS AND METHODS 
Ethics and surgical approval 
Rats used in this study were housed pre- and post-surgery according to the National 
Institutes of Health and the United States Department of Agriculture guidelines. Air in the 
cages was continuously refreshed and water and food were available ad libitum. At all 
times during the experiment, rats were kept within a double-barrier facility. All animal 
procedures were approved by the Institutional Animal Care and Use Committee at the 
Johns Hopkins University and the University of Pittsburgh. 
 
BMSC culture and lentiviral transduction 
BMSCs were harvested from the marrow of femurs of adult female Sprague-Dawley rats (n 
= 6, 200-230 g; Harlan, Indianapolis, IN, USA) according to previously described 
methods
44,45
. Lentiviral vectors (LV) encoding for green fluorescent protein (GFP) were 
used at an MOI of 150 to transfect BMSC at passage 0 to enable identification after 
transplantation
34
. BMSCs from the third passage were used for transplantation and of 
these 63 % expressed GFP as determined by FACScan/FACSorter (Becton Dickinson 
Immunocytometry Systems Biosciences, San Jose, CA, USA). The cells used for 
transplantation expressed the typical BMSC markers, CD90 and CD105 but not blood cell 




Spinal cord contusion 
Adult female Sprague-Dawley rats (n = 24, 200-230 g; Harlan) were sedated with 
intraperitoneal injections of 60 mg/kg Ketamine HCl (Phoenix Pharmaceuticals, St. Joseph, 
MD, USA) and 0.4 mg/kg medetomidine (Domitor®, an alpha-2-adrenergic agonist; Orion 
Corporation, Espoo, Finland). The back was shaved and cleaned with Betadine and 70 % 
alcohol, and Lacrilube ointment was applied to the eyes. The lower thoracic (T) spinal 
column was exposed, the T9 lamina was removed, and the underlying T10 spinal cord was 
contused using the Infinite Horizon Impactor (Precision Systems and Instrumentation, LLC, 
Lexington, Kentucky, USA) at 200 kdyn
45,46
. Two rats with recorded force and displacement 
that deviated over 5 % from the intended values were excluded. Two rats died before 
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receiving the contusive impact. The wound site was rinsed with phosphate-buffered saline 
(PBS) with 0.1 % gentamicin (Abbot Laboratories, North Chicago, IL, USA), the muscles 
were closed in layers using 5.0 sutures, and the skin was closed with Michel wound clips. 
Rats received a subcutaneous injection of 1.5 mg/kg atipamezole hydrochloride 
(antisedan®; an alpha-2-adrenergic antagonist; Pfizer Inc., New York, NY, USA) to reverse 
the sedative and analgesic effects of medetomidine. Ten ml lactated Ringer’s solution was 
injected subcutaneously and 6 mg/kg gentamicin (Abbott Laboratories) intramuscularly. 
The rats were kept at 37 °C until fully awake and were then returned to their cages. 
Between contusion and transplantation three days later, rats received daily 5 ml Ringer’s 
solution (subcutaneously), 6 mg/kg gentamicin (Abbot Laboratories; intramuscularly), and 
VA; subcutaneously) and the bladder was emptied manually twice per day.    
 
BMSC transplantation 
Three days post-contusion, rats were tested using the Basso-Beattie-Bresnahan rating 
scale (BBB test)
3,47
; three rats were removed from the study as their BBB score was higher 
than 5
4,34
. The remaining rats were sedated with intraperitoneal injections of 60 mg/kg 
Ketamine HCl (Phoenix Pharmaceuticals) and 0.4 mg/kg medetomidine (Orion 
Corporation). The T10 spinal cord segment was re-exposed and 1 x 106 BMSCs in DMEM 
(n = 9) or DMEM alone (control group; n = 8) (total volume was 5 µl in both cases) was 
injected into the contusion epicenter using a Hamilton syringe with a pulled glass needle 
attached (tip diameter: 150 μm) fixed within a micromanipulator
2
. The cells were injected 
over a 5 min period using an electronic micro-pump and the needle was kept in place for 
an additional 3 min. The wound site was closed in layers. The rats were kept at 37 °C until 
fully awake and then returned to their cages. The following three days, rats received daily 
5 ml Ringer’s solution (subcutaneously), 6 mg/kg gentamicin (Abbot Laboratories; 
intramuscularly), and 0.03 mg/kg Buprenorphin (Buprenex®; Reckitt Benckiser 
Pharmaceuticals Inc., Richmond, VA; subcutaneously). The bladder was emptied manually 
twice per day until reflex voiding occurred (± two weeks). Throughout the remainder of 
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the experiment rats were monitored daily; all rats survived without a need for treatment 
for pain or distress.  
 
Testing of locomotor function 
Overground locomotor recovery of automated hindlimb movements was assessed using 
the BBB test
3,47
 once a week for eight weeks post-injection over a 4 min period by two 
testers unaware of the treatments. Rats were familiarized with the open field and baseline 
values were confirmed. 
Higher motor functions were assessed using the BBB sub-score
48
. In the predominant paw 
we determined position (internal/external at initial contact (IC) and liftoff (0 points), 
parallel at IC and internal/external at liftoff or vice versa (1), parallel at IC and liftoff (2)), 
toe clearance (none (0), occasional (1), frequent (2), consistent (3)), tail position (down (0), 




Locomotion pattern was assessed using footprint analysis (modified from de Medinaceli et 
al.
49
). Before (baseline) and at four and eight weeks post-injection, the forepaws were 
dipped in red ink and the hindpaws in blue ink and footprints were recorded during 
walking across a paper track (100 cm long, 7 cm wide) and used to measure angle of 
hindpaw rotation, hindlimb base of support, and hindlimb stride length. Average values 
per paw were calculated from at least five sequential steps. Values for both hindpaws 
were averaged. Hindpaw rotation was defined by the angle formed by the intersection of 
the line through the prints of the third digit and the metatarsophalangeal joint and the 
line through the central pad parallel to the walking direction. Hindlimb base of support 
was determined by measuring the core to core distance of the hindpaws central pads. 
Hindlimb stride length was defined by the distance between the central pads of two 
consecutive prints. At the time of footprint testing all rats exhibited weight support.  
Sensorimotor function of the hindlimbs was assessed before (baseline) and at four and 
eight weeks post-injection using horizontal ladder walking
50
. Rats walked across a 100 cm 
long horizontal ladder three times each test. The passages were videotaped and played 
back in slow-motion for accurate evaluation. Only the middle 60 cm of the ladder was 
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used for measurements. Small (foot or part of foot), medium (foot and part of lower leg), 
and large (full leg) slips were counted and individually and collectively expressed as a 
percentage of the total number of steps.  
 
Testing of sensory function 
Thermal hyperalgesia (i.e., an increased response to a nocuous stimulus) was measured at 
four and eight weeks post-injection by assessing the withdrawal response time to a heat 
source applied using a Hargreaves’ heat source
51
. Rats were acclimated for 5 min before 
measurements in a Plexiglas test box with an elevated mesh floor. The radiant heat source 
with constant intensity was aimed at the mid-plantar area of each hindpaw and the time 
(in sec) until limb withdrawal was recorded. The heat source automatically shuts down at 
15 sec to prevent injury. The resting interval between measurements was 20 min. All rats 
withdrew their limb before the cut-off time was reached. Baseline measurements were 
taken before contusion. Three middle measurements out of five of each paw were 
averaged and expressed as a percentage of the baseline.  
Mechanical allodynia (i.e., a pain-related response to a normally innocuous stimulus) was 
measured at four and eight weeks post-injection by assessing the force to the hindpaw 
resulting in limb withdrawal. Rats were acclimated for 5 min before measurements in a 
Plexiglass test box with an elevated mesh floor. An electronic von Frey anesthesiometer
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was applied perpendicularly to the mid-plantar area of each hindpaw and the pressure 
increased until limb withdrawal. The force (in g) at withdrawal was recorded. Before 
contusion baseline measurements were taken. Three middle measurements out of five of 
each paw were averaged and expressed as a percentage of the baseline.  
 
Retrograde neuronal tracing 
After the last functional tests were completed, rats were injected with 1.2 µl fast blue (FB) 
at 7 mm caudal to the contusion epicenter (between vertebrae T10 and T11) to 
retrogradely label neurons with an axon projecting caudal to the contusion/transplant. 
The tracer was injected in 6 deposits of 0.2 µl using a glass needle (approx. diameter: 150 





One week after retrograde tracer injections, rats were anesthetized with an 
intraperitoneal injection of 60 mg/kg Ketamine HCl (Phoenix Pharmaceuticals) and 0.4 
mg/kg medetomidine (Domitor®, Orion Corporation). After deep sedation was confirmed, 
the heart was exposed and 0.1 ml Heparine (500 IU; Henry Schein, Melville, NY, USA) was 
injected into the left ventricle. Next, 300 ml saline followed by 500 ml 4% 
paraformaldehyde in phosphate buffer (PB; 0.1 M, pH 7.4) was pumped through the 
cardiovascular system. The spinal cord and brain were removed and post-fixed overnight 
in the same fixative at 4 °C. The brainstem, motor cortex, and a ten mm long spinal cord 
segment centered at the contusion site were transferred to phosphate-buffered 30% 
sucrose. These tissue blocks were embedded in Shandon M-1 Embedding Matrix (Thermo 
Electron Corporation, Pittsburgh, PA) and cut on a Leica CM 1950 cryostat. The spinal cord 
segment was cut into ten series of 20 µm-thick horizontal sections and the brainstem and 
motor cortex were cut into ten series of 40 µm-thick transversal sections. The sections 
were mounted onto glass slides and stored at −20 °C until further processing. One series 
of sections was stained with cresyl violet to demonstrate the cytoarchitecture of the 
contused segment. Another series was stained with luxol fast blue to demonstrate 
presence of myelin.  
 
Immunohistochemistry 
Four series of cryostat sections were permeabilized with 0.3% Triton X-100 in PB (0.1 M, 
pH 7.4), immune-blocked with 5% normal goat serum in PB at room temperature for 30 
min, and then immunostained
53
. The following primary antibodies were used: polyclonal 
rabbit antibodies against glial fibrillary acidic protein (GFAP, 1:200; Incstar Corp., 
Stillwater, MN), and monoclonal mouse antibodies directed against rat endothelial cells 
(RECA-1 (20), 1:100; AbD Serotec, Raleigh, NC). Then, the sections were washed with PBS 
and incubated for 2 h at room temperature with goat-anti-mouse IgG or goat-anti-rabbit 
IgG coupled to Alexa Fluor® 594 (1 : 200; Molecular Probes). Staining specificity was 
confirmed by omitting the primary antibody. Stained sections were covered with glass 
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slips with Vectashield with DAPI (Vector Laboratories, Inc., Burlingame, CA) and kept 
refrigerated until analysis.  
 
Measurement of spinal cord tissue sparing 
Cresyl violet-stained sections were used to determine in a blinded fashion the volume of 
spared tissue in each spinal cord using the Cavalieri estimator function of Stereo 
Investigator® (MicroBrightField Inc.). The Gundersen Coefficient of Error was < 0.05 for all 
measurements. In each tenth section the volume of spared tissue in a 3.4 mm long 
segment centered at the contusion epicenter was determined. Within the analyzed 
segment, tissue was considered spared if it lacked cavities, areas with densely packed 
small cells resembling infiltrated neutrophils and lymphocytes, and neurons with darkly 
stained cytoplasmic Nissl bodies
2,34,43
. The volume of spared tissue was expressed as a 
percentage of the average volume of a comparable uninjured spinal cord segment. 
 
Measurement of blood vessel density 
One series of sections was stained with RECA-1 antibodies
54
 and used to determine the 
blood vessel density (RECA-1-positive blood vessels per tissue surface area) using Stereo 
Investigator® (MicroBrightField Inc.) in a blinded fashion. In each tenth section, at 20 x 
magnification, three areas were analyzed; the epicenter, rostral to the epicenter, caudal to 
the epicenter. Within each area, three samples were taken (320 x 420 µm each) in which 
all RECA-1-positive structures were outlined. In most cases, the measuring area of the 
three contiguous samples was larger than the width of the spinal cord in the epicenter but 
smaller than the width just rostral and caudal to the epicenter. Therefore, we normalized 
the blood vessel surface area for the measured tissue surface area to get the blood vessel 
density (blood vessel area per 0.1 mm
2
). The values per level in each section were 
averaged to give the blood vessel density per level per rat.  
 
Quantification of GFP-positive BMSCs and FB-positive neurons 
One series of spinal cord cryostat sections was covered with a glass slip with Vectashield 
with DAPI (Vector Laboratories, Inc.) and used to determine the number of GFP-positive 
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BMSCs in the contusion using Stereoinvestigator (MicroBrightField Inc., Colchester, 
Virginia, USA). In each tenth section with GFP-positive cells, the transplanted area was 
outlined manually at 4 x magnification and covered with a 250×250 µm grid. At 60 x 
magnification with oil immersion, GFP-positive cells were marked using the optical 




One series of brainstem and motor cortex sections was covered with a glass slip with 
Vectashield (Vector Laboratories, Inc.). FB-positive cells in the red nuclei, reticular 
formation, vestibular nuclei, raphe nuclei, and motor cortex (hindlimb area) were counted 
by an investigator unaware of the treatments. FB-labeled neurons counted in the 
gigantocellular reticular formation and raphe nuclei were summed because these nuclei 
are difficult to distinguish from each other. All numbers were multiplied by 10 to obtain 





Student T-test and, in case of multiple time points, repeated measures ANOVA followed 
by Tukey’s post hoc test were used to determine statistical differences between groups. 
Differences were accepted as statistically significant at P < 0.05. Correlation analysis was 
used to determine the relationship between variables and expressed by the coefficient of 
determination (r
2
) and the significance level (p). Relationships were considered strong 
when r
2
 > 0.25 and accepted when p < 0.05. 
 
RESULTS 
BMSC-transplants elicited tissue sparing 
Spared tissue volume in a 3.4 mm long segment centered at the contusion (Fig. 1A) was 
determined in BMSC-transplanted rats (Fig. 1B) and control rats (Fig. 1C) at eight weeks 
post-injection. With a BMSC transplant the volume of spared tissue relative to that of a 
similar spinal cord segment in an uninjured/untreated rat was 24.8 ± 1.4 % (SEM), which 
represented a significant 66 % increase (p < 0.01) in tissue sparing compared to controls 
(14.9 ± 1.6 %; Fig. 1D). The tissue that was spared in BMSC-transplanted rats consisted 
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mostly of white matter (97.03 ± 2.6 %) and little of gray matter (2.97 ± 2.6 %; Fig. 1E). In 
three out of nine BMSC-transplanted rats, GFP-positive BMSCs were present in the 
contusion at eight weeks post-injection (Fig. 1F). Some of these BMSCs were round and 
other elongated (Fig. 1G). The total numbers of BMSCs in these three rats were 3937 (0.4 
% of injected number of cells), 11460 (1.1 %), and 13429 (1.3 %). In all rats, the contusion 
epicenter was surrounded by GFAP immunostaining, which was used to identify the 
contusion epicenters (Fig. 1H, 1I).  
 
Rats with BMSCs demonstrated improved motor and sensorimotor functions 
Overground walking ability (Fig. 2A) was not different (repeated measures ANOVA) 
between treatment groups. Both groups had a final score of about 11 (Fig. 2B) indicating 
frequent to consistent weight-supported plantar stepping without forelimb-hindlimb 
coordination. Higher locomotor functions were significantly different (repeated measures 
ANOVA) between groups (F (1, 126) = 240.6; p < 0.0001). The final score was 4.0 ± 0.3 
(SEM) in rats with BMSC and 1.8 ± 0.3 in controls (Fig. 2C).  
Footprint analysis (Fig. 2D) revealed a significant difference between groups in angle of 
hindpaw rotation (repeated measures ANOVA: F (1, 20) = 28.5; p < 0.0001; Fig. 2E) and 
hindlimb base of support (F (1, 20) = 15.6; p < 0.001; Fig. 2F) but not hindlimb stride length 
(P = 0.29; Fig. 2G). The angle of rotation of rats with BMSCs  
was 38.6 % smaller (M = 17.8; 95% Cl [15.8, 19.8]) at four weeks and 25.7 % smaller (M = 
19.8; 95% Cl [18.8, 20.8]) at eight weeks post-injection compared to controls (M = 29.0; 
95% Cl [26.3, 31.7] and M = 26.5; 95% Cl [26.0, 27.0], respectively; Fig. 2E). At eight weeks 
post-injection, external rotation of the hindpaws was increased in BMSC-transplanted rats 
compared to baseline (Fig. 2E). The base of support of BMSC-transplanted rats was 17.0 % 
smaller (M = 39.0; 95% Cl [36.0, 42.0]) at four weeks post-injection compared to controls 
(M = 47.0; 95% Cl [45.0, 49.0]) and similar at eight weeks post-injection (Fig. 2F). At the 
later time point, the base of support in transplanted rats was 12.3 % larger than baseline 
(Fig. 2F).Horizontal ladder walking (Fig. 3A) was significantly different between groups 
(repeated measures ANOVA: F (1, 24) = 24.8; p < 0.0001). The numbers of slips was 
expressed as a percentage of the total number of steps needed to cross the measuring 
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area (average of both groups: 14.4 ± 0.2 (SEM) at four and 15.0 ± 0.3 at eight weeks). For 
total slips, the improvement in rats with BMSCs was 66.0 % at four weeks (M = 32.1; 95% 
Cl [28.9, 35.3]; Fig. 3B) and 69.6 % at eight weeks (M = 21.4; 95% Cl [18.8, 24.0]; Fig. 3C) 
compared to controls. and 1545 ± 220 in white matter only. The blood vessel density in 
epicenter white matter in BMSC-transplanted rats was significantly (p < 0.01) 4.5-fold 
higher than in controls and 2.3-fold higher than in uninjured rats (Fig. 5E).  
 
BMSC-transplanted rats had improved sensory functions 
Thermal hyperalgesia (Fig. 4A) was significantly decreased in rats with BMSCs compared to 
controls (repeated measures ANOVA: F (1, 0.41) = 53.5; p < 0.0001; Fig. 4B). The 
improvement was 43.7 % (M = 10.2; 95% Cl [9.9, 10.5]) at four weeks and 24.6 % (M = 7.6; 
95% Cl [7.3, 7.9]) at eight weeks post-injection (M = 7.1; 95% Cl [6.7, 7.5] and M = 6.1; 95% 
Cl [5.8, 6.4], respectively; Fig. 4B).  
Mechanical allodynia (Fig. 4C) was significantly decreased in rats with BMSCs compared to 
controls (repeated measures ANOVA: F (1, 24) = 26.9; p < 0.0001; Fig. 4D). The 
improvement was 34.7 % at four weeks post-injection (M = 96.9; 95% Cl [94.2, 99.6]) and 
51.7 % (M = 88.0; 95% Cl [85.8, 90.2]) at eight weeks post-injection (M = 72.3; 95% Cl 
[70.0, 74.6] and M = 58.2; 95% Cl [56.5, 59.9], respectively; Fig. 4D). Table 1 provides an 
overview of the functional test results. 
 
Rats with BMSCs had higher blood vessel density in the contusion epicenter 
The density of blood vessels was assessed in the contusion epicenter, the white matter in 
the epicenter, and outside of the epicenter (Fig. 5A). In the epicenter, blood vessels were 
mostly larger and with fewer branches (Fig. 5B) than outside of 
the contused area (Fig. 5C). The blood vessel density in the epicenter was significantly (p < 
0.001) 6.5-fold higher in BMSC-transplanted rats than in controls (Fig. 5D). Outside of the 
epicenter there were no significant differences between groups (Fig. 5D), which was in 
agreement with previous reports
55
. The latter value was similar as that found in the 
epicenter in BMSC-transplanted rats and in the spinal cord of uninjured rat (Fig. 5D). In 
uninjured rats the average blood vessel density was 4922 ± 397(SEM) in the spinal cord,  
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Fig. 1. BMSCs increased the amount of spared tissue in the contusion epicenter. Spared tissue volumes were 
determined at eight weeks post-transplantation within a 3.4 mm long spinal cord segment centered at the 
contusion (A) in BMSC-transplanted rats (B) and controls (C). BMSCs elicited a neuroprotective effect as the 
spared tissue volume in transplanted rats was significantly (p < 0.01) 66 % larger than in controls (D). In BMSC-
transplanted rats, 97 ± 2.6 % of the spared tissue consisted of white matter (E). Three out of nine transplanted 
rats had GFP-positive BMSCs in the contusion (F), which exhibited largely variable morphologies (G). GFAP-
positive astrocytes were present in the contusion epicenter in all rats (H). In most rats, GFAP-positive astrocytes 
were found within tissue strands in the epicenter (I). Note panel I is outlined in panel H. Bar in B is 500 µm. Bar in 
C is 500 µm. Bar in F is 250 µm. Bar in G is 50 µm. Bar in H is 500 µm. Bar in I is 250 µm. 
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8299 ± 645 in gray matter only, and 1545 ± 220 in white matter only. The blood vessel 
density in epicenter white matter in BMSC-transplanted rats was significantly (p < 0.01) 




Fig. 2. BMSCs improved locomotion-related features/pattern but not overground walking. With the BBB test (A) 
we found that BMSC-transplanted and control rats exhibited similar overground walking abilities throughout 
survival (B). The baseline (21) is indicated by the horizontal broken line. The BBB sub-score revealed that higher 
motor functions in BMSC-transplanted rats were significantly (p < 0.0001) better than in controls (C). Footprint 
analysis was used to assess locomotion pattern by measuring the angle of hindpaw rotation, base of support, and 
stride length (D). Hindpaw rotation in BMSC-transplanted rats was significantly (p < 0.01) improved by 39 % at 
four and 26 % at eight weeks post-injection compared to controls (E). At eight weeks, external rotation of the 
hindpaws in BMSC-transplanted rats was increased compared to baseline (15 ± 2.1; horizontal broken line). Base 
of support was 17 % improved (p < 0.01) in rats with BMSCs compared to controls at four weeks but similar at 
eight weeks post-injection (F). At the eight week time point, the base of support in rats with BMSCs was 12 % 
larger than baseline (34.2 ± 2.2; horizontal broken line). Stride length was similar between groups at both 
measuring time points (G) and not different from baseline (105 ± 8.3; horizontal broken line in G).  
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Fig. 3. BMSCs improved horizontal ladder walking performance. The number of small, medium, and large slips (A) 
at four and eight weeks post-injection were quantified and expressed as a percentage of the total number of 
steps used to cross the ladder. Rats with BMSCs performed significantly (p < 0.0001) better than controls at four 
(B) and eight (C) weeks post-injection. BMSC-transplanted rats made 66 % less total mistakes at four weeks and 
70 % less at eight weeks post-transplantation. 
 
Rats with BMSCs had more brainstem neurons projecting beyond the contusion 
Retrograde FB tracing was used to identify brainstem and motor cortex neurons with an 
axon beyond the contusion site. Figure 6 provides examples of FB-labeled neurons present 
in the nucleus raphe obscurus (Fig. 6A, 6B) and the reticular 
formation (Fig. 6C, 6D). In transverse brainstem sections FB-labeled neurons were plotted 
and quantified in the red nucleus (Fig. 6E), reticular formation (Fig. 6F), 
vestibular nuclei (Fig. 6G), gigantocellular reticular nucleus (Fig. 6G), and raphe nuclei (Fig. 
6H). No labeled neurons were found in the hindlimb area of the motor cortex. The total 
number of FB-labeled brainstem neurons in rats with BMSCs was  
7650 ± 765; a significant twofold increase (p < 0.05) over controls (Fig. 6I). There were 2.2-
fold more labeled neurons in the reticular formation (p < 0.05), threefold more in 
vestibular nuclei (p < 0.05), and twofold more in raphe nuclei (including the gigantocellular 
reticular formation; p < 0.05) in rats with BMSCs compared to controls (Fig. 6I). The 
number of FB-labeled neurons in the red nuclei was similar in both groups (Fig. 6I). With 
correlation analysis a strong significant association was identified between tissue sparing 
and total brainstem neurons (r
2




Fig. 4. BMSCs decreased thermal hyperalgesia and mechanical allodynia. Thermal hyperalgesia was assessed 
using a Hargreaves’ heat source (A) which revealed that rats with a BMSC transplant had significantly (p < 0.0001) 
longer hindpaw withdrawal response times (i.e., improved tolerance) than controls (B). The improvement was 44 
% at 4 weeks and 25 % at eight weeks after BMSC transplantation. At eight weeks post-injection, thermal 
hyperalgesia in BMSC-transplanted rats was 49 % above baseline (15 ± 1.8; horizontal broken line). With an 
electronic von Frey anesthesiometer (C) we found that mechanical allodynia in BMSC-transplanted rats was 
significantly (p < 0.0001) improved compared to controls (D). The improvement in tolerance to pressure to the 
hindpaws was 35 % at 4 weeks and 52 % at eight weeks after BMSC transplantation. At the latest time point, 









Table 1. Functional improvements at four and eight weeks after BMSC transplantation into the 
contused adult rat spinal cord.  














4 wks -  6.4x -  17.0%  36.8%  66.0%  43.7%  34.7% 
         
8 wks -  2.2x - -  25.7%  69.6%  24.6%  51.7% 
An upward arrow represents a statistically significant improvement in test performance of BMSC-transplanted 
rats compared to controls. A dash represents no difference between BMSC-treated rats and controls. 
 
Relationships between tissue sparing, motor/sensory functions, blood vessel density, 
and brainstem neurons projecting beyond the contusion 
Tissue sparing and motor/sensory functions (Table 2). A strong significant functional 
relationship was present between tissue sparing and BBB sub-score (r
2
 = 0.87, p < 0.001), 
angle of rotation (r
2
 = 0.81, p = 0.001), horizontal ladder walking (r
2
 = 0.74, p= 0.001), and 
thermal hyperalgesia (r
2
 = 0.56, p = 0.013). Relationships between tissue sparing and BBB, 
hindlimb stride length and base of support, and mechanical allodynia were not significant. 
Motor/sensory function and brainstem neurons (Table 3). Strong significant functional 
relationships were found between raphe neurons and the BBB subscore (r
2
 = 0.78, p = 
0.002), angle of rotation (r
2
 = 0.68, p = 0.007), and horizontal ladder (r
2
 = 0.54, p = 0.02). 
Strong relationships were also found between the total brainstem neurons and the BBB 
subscore (r
2
 = 0.76, p = 0.002), angle of rotation (r
2
 = 0.51, p = 0.03), and horizontal ladder 
(r
2
 = 0.54, p = 0.02). Reticular neurons had a strong significant relationship with BBB (r
2
 = 
0.60, p = 0.008) and BBB sub-score (r
2
 = 0.50, p = 0.03).  
Tissue sparing and blood vessel density. We found a strong significant functional 
relationship between spared tissue volumes and blood vessel density in the epicenter in 
general (r
2
 = 0.67, p = 0.004) and in white matter only (r
2
 = 0.47, p = 0.04). 
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Fig. 5. BMSCs increased blood vessel density in the contusion epicenter. RECA-1 antibodies were used to identify 
blood vessels rostral, within, and caudal to the contusion epicenter (A). The blood vessels in the epicenter were 
generally longer, more straight, and with fewer branches (B) than outside the epicenter (C). In the epicenter 
blood vessel density was significantly (p < 0.001) higher in rats with BMSCs than in controls (D). Outside the 
epicenter the blood vessel density in both groups was similar and comparable to that in uninjured rats (average 
indicated by horizontal broken line). In white matter only in the epicenter, the blood vessel density was 
significantly (p < 0.01) higher in BMSC-transplanted rats than in controls or uninjured rats (E). Bar in B represents 
35 µm in B and C. 
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Fig. 6. BMSCs increased the number of brainstem axons caudal to the contusion. We used retrograde FB tracing 
to identify brainstem and motor cortex neurons projecting beyond the contusion. Labeled neurons were found in 
several brainstem nuclei including the nucleus raphe obscures, shown here at 10 X (A) and 20 X (B), and the 
reticular formation, shown here at 20 X (C, D). FB-labeled neurons (represented by red dots) were found in the 
red nucleus (E), reticular formation (F), vestibular and gigantocellular reticular nuclei (G), and the nucleus raphe 
obscurus and nucleus raphe pallidus (H). The level of brainstem sections shown in E-H is provided relative to 
Bregma (B). Rats with BMSCs had significantly (p < 0.05) more FB-labeled neurons in their brainstem than 
controls (I). Significantly higher numbers (p < 0.05) were found in the reticular formation, vestibular nuclei, and 
raphe nuclei, but not the red nucleus (I). On average the increase in FB-labeled neurons in BMSC-transplanted 




Table 2. Relationship between tissue sparing and motor/sensory functions at eight weeks after 
BMSC transplantation into the contused adult rat spinal cord.  
Correlation analysis was employed to examine the functional relationships between the outcome measures at 
eight weeks post-injection. The table provides the coefficient of determination (r2, top) and the significance level 
(P value, bottom). Strong statistically significant relationships between spared tissue volumes and neuron 
numbers (r2 > 0.25, P < 0.05) are shaded in gray. Abbreviations: BBB = Basso-Beattie-Bresnahan. 
 
Table 3. Relationship between brainstem neurons and motor/sensory functions.  
We used correlation analysis to assess the functional relationships between the outcome measures at eight 
weeks post-transplantation. The table lists the coefficient of determination (r2, top) and the significance level (P 
value, bottom). Statistically significant strong relationships between neuron numbers and function (r2 > 0.25, P < 
0.05) are shaded in gray. Abbreviations: BBB = Basso-Beattie-Bresnahan. 
 
 










































































































































We found that a BMSC transplant in the contused spinal cord of adult rats elicits tissue 
sparing which correlated strongly with improvements in higher motor functions, hindpaw 
rotation, horizontal ladder walking, and thermal hyperalgesia. The data also revealed that 
rats with BMSC elicited an angiogenic response in the contusion epicenter which 
correlated with tissue sparing. Retrograde tracing revealed that rats with BMSCs had 
significantly more brainstem neurons with an axon projecting beyond the contusion which 
correlated with improved motor functions but not sensory functions. Together, the data 
indicate that BMSC transplants in the adult rat contused spinal cord result in tissue sparing 
which is differentially involved in functional restoration. Blood vessel 
preservation/formation and descending brainstem axon sparing/regeneration appear 
important mediators of the BMSC-mediated improved outcomes.  
 
Transplantation of BMSCs into the contused adult rat spinal cord resulted in a significant 
66 % increase in spared tissue volume in the injury epicenter. This finding is consistent 
with previous studies
25,30,34
. Tissue sparing was determined at eight weeks post-
transplantation. At this time point almost all BMSCs had died; few were present in only 
three of the transplanted rats. Therefore, it is unlikely that the transplanted cells 
contributed significantly to the volume of spared tissue. We showed previously that 
BMSCs transplanted into the contusion at three days post-injury survive poorly with 50 % 
lost after one week and almost all lost after four weeks
34
. Interestingly, the relative short 
duration of BMSC presence in the contusion is sufficient to elicit a significant tissue 
sparing effect. The neuroprotective effect of BMSC transplants is not present with delayed 
(seven and twenty-one days) injection paradigms
34
, which indicates the existence of a 
specific (sub)acute therapeutic window for BMSC-mediated neuroprotection.  
 
The mechanisms underlying BMSC-mediated tissue sparing are largely unknown. In search 
for mediators of this effect we identified blood vessels to be a possible candidate. After 
injury the loss of blood vessels decreases the spinal cord blood flow which correlates with 
nervous tissue loss
56
. We show here that rats with BMSCs transplants have significant 
66 
higher blood vessel densities in the contusion epicenter and that this was strongly 
associated with spared tissue volumes. Transplanted BMSCs secrete the proangiogenic 
vascular endothelial growth factor (VEGF)
57





 of blood vessels in injured nervous tissue. Through both mechanisms, 
BMSCs could have contributed to tissue sparing in the contusion epicenter.  
 
A positive relationship between blood vessel density and spared tissue volumes in the 
injured spinal cord has been proposed before for adult rats
55
 but not for adult guinea 
pigs
60
. The latter study revealed a correlation between blood vessel density and secondary 
loss of function indicating a role of hypervascularity in secondary pathology
60
. Our present 
results are in variance with this idea as they show greater improvements in neurological 
function in rats with higher blood vessel density in the contusion. Further studies are 
required to elucidate the role of hypervascularity in spinal cord repair.  
 
BMSC transplantation resulted in improved motor, sensorimotor, and sensory functions 
which, with the exception of mechanical allodynia, strongly correlated with spared tissue 
volumes. In fact, based on our findings, over 70 % of the variability in higher motor and 
sensorimotor function and 56 % of that in thermal hyperalgesia can be attributed to a 
linear relationship with spared tissue volume. These results highlight a significant 
involvement of tissue sparing in functional restoration after a spinal cord contusion and 
emphasize the relevance of treatment that focus on tissue sparing as an early intervention 
in spinal cord repair strategies. 
 
The behavioral improvements in our study seemed more pronounced during the first 
month after transplantation compared to the second month. Currently, it is unknown 
whether functional improvements due to BMSC transplantation remain present 
permanently.  It is possible that the deteriorating general health due to spinal cord injury 
affects function negatively. Also, benefits from the BMSC transplant may be temporary 
due to the poor transplant survival. Future studies will be required to address these 
important clinically relevant issues. 
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The precise mechanisms underlying the relationship between spared tissue and motor and 
sensory functions are poorly understood. Tissue sparing likely includes a variety of cellular 
consequences which each exert their specific effect on behavioral recovery. We examined 
more closely to what extent descending axons from brainstem neurons were involved in 
the observed functional improvements. Different types of descending brainstem axons are 
involved in motor function
61-63
. We demonstrated in this study that the large majority of 
spared tissue in BMSC-transplanted rats is white matter. Thus it is possible that increased 
amounts of spared tissue reflect more spared axons descending to lower spinal cord 
segments involved in motor functions. We found here that rats transplanted with BMSC 
had a twofold increase in number of (retrogradely FB-labeled) brainstem neurons 
projecting their axon beyond the contusion compared to controls. The correlative analysis 
further indicated that these brainstem neurons were involved in over 40 % (coefficient of 
determination, r2 > 0.4) of the observed recovery in higher motor and sensorimotor 
function, but did not contribute to recovery in sensory functions (r2 < 0.2).  
 
Among the brainstem neurons, raphe neurons were strongly correlated with higher motor 
functions and sensorimotor function and reticular formation neurons with higher motor 
functions and overground walking. Descending raphespinal axons have been implicated in 
initiating and modulating motor behaviors through the central pattern generator
64,65
. 
Reticulospinal axons have been associated with flexion during the swing phase and 
extension during the stance phase
66
, which may explain their association with walking and 
higher motor functions.  
 
BMSC-transplanted rats exhibited significantly improved higher motor functions as 
revealed with the BBB sub-scoring scale
48,64
 and footprint analysis. Transplantation of 
BMSCs also significantly enhanced horizontal ladder walking with fewer small, medium, 
and total slips indicating enhanced integration of sensory and motor inputs
50
. 
Interestingly, the combined improvements did not result in improved overground walking 
as examined using the BBB test. A lack of improved walking in rats with a BMSC transplant 
was reported previously by some
30-33
 but not by others
e.g., 23,24,27
. The absence of improved 
68 
walking could reflect the complexity of properly rating increasing degrees of forelimb-
hindlimb coordination. This convolution has been recognized and resulted in the design of 
the BBB sub-scoring scale to increase the sensitivity of the BBB rating scale for rats that 
lack coordination
48,64
. An alternative explanation for the lack of improved walking in the 
present study is that mechanisms underlying recovery in overground walking are in part 
different from those underlying recovery of higher motor and sensorimotor functions. This 
possibility needs to be considered because elucidating the different mechanisms would be 
imperative for the design of more effective and comprehensive spinal cord repair 
approaches. 
 
BMSC-transplanted rats exhibited less sensitivity to mechanical and thermal stimuli to the 
hindpaws, which is an improvement over the typically observed contusion-induced 
hypersensitivity. To our knowledge only one study has investigated the effects of a BMSC 
transplant on sensory function in rats with a contused spinal cord. Himes and colleagues
23
 
reported that transplantation of BMSCs did not affect thermal hyperalgesia. A possible 
explanation for this discordance with our study is the difference in time of BMSC 
transplantation; three days post-injury in our study and seven days post-injury in Himes et 
al
23
. We have previously shown that transplantation of BMSCs into a contused adult rat 
spinal cord at seven days post-injury leads to significantly less tissue sparing than 
transplantation at three days after injury
34
. We show in the present study that tissue 
sparing is correlated with thermal hyperalgesia reduction. Thus, less tissue sparing after a 
7-day delayed BMSC transplantation may have caused the observed lack of improvements 
in thermal hyperalgesia in Himes et al.
23 
 
The injury-induced inflammatory response may contribute to the development of thermal 
hyperalgesia
e.g.,67
. BMSC transplantation has been associated with reduced 
inflammation
68,69
. Thus, it is possible that in our study the decrease in thermal 
hyperalgesia in transplanted rats reflects a BMSC-mediated decrease in inflammation, 
which may also contribute to tissue sparing
70
. On the other hand, we showed that BMSC 
transplantation into a three-day old spinal cord contusion does not lead to a decrease in 
69 
the number of macrophages
45
. Further studies are needed to elucidate the interactions 
between inflammation, thermal hypersensitivity, and tissue sparing following spinal cord 
injury and repair.      
The present and previous studies suggest that optimal BMSC neuroprotective effects are 
obtained within a three-day (or acute) transplantation paradigm, suggesting clinical 
translation would favor allograft transplantation, because culturing an autograft would 
take more time. On the other hand, a human bone marrow biopsy, combined with cell 
sorting strategies, might provide an adequate amount of BSMCs to enable timely 
autograft transplantation. Additional research will be needed to investigate the 
applicability and efficacy of such autografts. 
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The ability of bone marrow stromal cell (BMSC) transplants to elicit spinal cord repair is 
thought to result from paracrine effects by secreted trophic factors including brain-
derived neurotrophic factor (BDNF). Here we used gene therapy to increase or silence 
BDNF production in BMSCs and investigated the involvement of BDNF in BMSC-mediated 
neuroprotection. In a spinal cord organotypic culture, conditioned medium of BMSCs with 
normal, increased, or decreased BDNF enhanced spinal motoneuron survival averagely 64 
% compared with culture medium only. Only with conditioned medium of BMSCs with 
increased BDNF this neuroprotective effect was sustained. In a rat model of spinal cord 
contusion, at four weeks post-injury, tissue sparing was 68% improved with a sub-acute 
transplant of BMSCs with increased or normal BDNF compared with BMSCs with 
decreased BDNF and without transplant. Motoneuron survival in the contusion with 
BMSCs with increased BDNF was 33 % higher compared with any other group. Blood 
vessel density in the contusion with BMSCs with increased BDNF was 35 % higher 
compared with BMSCs with normal BDNF and 6-fold higher compared with no transplant. 
BMSCs with decreased BDNF resulted in a 76 % decrease in blood vessel density compared 
with BMSCs with normal BDNF. Our data show that increased BDNF augments BMSC-




Transplantation of bone marrow stromal cells (BMSCs)
1,2
 in the injured spinal improves 
functional recovery
3-9
. BMSCs elicit neuroprotection
3-6
 in the damaged spinal cord which is 
correlated with functional recovery
3
. How BMSCs elicit neuroprotection is poorly 
understood. It is thought that BMSCs secrete trophic factors exerting paracrine effects
9-16
, 
but which and how trophic factors are involved in BMSC-mediated neuroprotection is 
unknown.  
Protection of neurons in the damaged spinal cord nervous tissue may result from 
neurotrophic factors
17,18
. BMSCs secrete neurotrophic factors including brain-derived 
neurotrophic factor (BDNF)
14-16
. BDNF exerts trophic effects on neurons in vitro and in 
vivo
19-21
. Administration of BDNF to the injured spinal cord leads to neurotrophic effects 
including neuronal sparing
22-25
. Transplantation of BMSCs genetically modified to 
overexpress BDNF improves neuroprotection and repair
26-28
. BDNF is also known to be 
involved in vascular events
25,29-33
, including protecting blood vessels from injury-induced 
loss, which could also support neuroprotection
34-36
. Together these data validate the 
candidacy of BDNF as a determinant in BMSC-mediated neuroprotection.  
Here, we hypothesized that BDNF secreted by BMSCs is associated with neuronal and 
vascular sparing in the contused adult rat spinal cord. Gene therapy was used to modulate 
the secretion of BDNF by BMSCs. To assess the effect of the gene modulations we used a 
spinal cord organotypic culture to investigate motoneuron survival, and an adult rat model 
of spinal cord contusion to investigate motoneuron survival, blood vessel density, and 
nervous tissue sparing.   
 
METHODS 
BMSC culture and lentiviral transduction 
BMSCs were harvested from femurs from adult female Sprague Dawley rats (200-250 g; 
Charles River Laboratories, Wilmington, MA) and cultured as previously described
3,37
. 
After one passage, BMSCs were transduced with lentiviral vectors (LV) encoding for BDNF 
and green fluorescent protein (GFP; LV-BDNF/GFP) to upregulate BDNF, LV-
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BDNFshRNA/GFP to knock down BDNF (five different constructs; clones were purchased 
from OpenBiosystems; cat. #.: RMM4532-NM-012513), or LV-GFP for controls. LVs were 
produced by the Viral Vector Core Facility of the Miami Project to Cure Paralysis 
(University of Miami Miller School of Medicine, Miami, FL) and used at a multiplicity of 
infection of 100. Transduced BMSCs were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) with 10 % Fetal Bovine Serum and 1 % Penicillin/Streptomycin and passaged 
every three days. Passage 4 (P 4) BMSCs were used for transplantation.  
 
In vitro analysis of BMSCs 
Lentiviral transduction of BMSCs in culture was confirmed by verifying stable GFP 
expression for seven passages. BMSCs in culture were characterized using immunostaining 
for CD90, CD105, CD45, TrkB and P75 (see below). Culture medium from confluent P 4 
BMSC cultures (2 x 10
6
 cells) was collected after 24 hours to quantify the amount of 
secreted BDNF using enzyme-linked immunosorbent assay (ELISA; Promega, Madison, Wi, 
USA) according to the manufacturer’s guidelines. Unconditioned culture medium was used 
as a negative control. Three biological replicates were quantified per condition and each 
biological replicate was the average of two technical replicates.  
 
Motoneuron survival in spinal cord organotypic cultures 
The effect of culture medium conditioned by the differently transduced BMSCs on 
motoneuron survival was determined using spinal cord organotypic slices prepared from 
neonatal (postnatal days 1-4) B6.Cg-Tg(Thy1-YFP)16Jrs/J transgenic mice (Jackson 
Laboratories, Maine, MA) in which spinal motoneurons express (Thy1-driven) yellow 
fluorescence protein (YFP). The spinal cord was dissected and transferred into dissection 
medium containing Hank’s balanced salt solution (Gibco, Carlsbad, CA) with 4.3 mM 
NaHCO3, 10 mM Hepes, 33 mM glucose, 0.03 % BSA, 0.15 % MgSO4-7H2O, 100 U/ml 
penicillin, and 100 U/ml streptomycin. After removal of dura and meninges, the spinal 
cord was transversely sliced at 350 µm on a McIllwain tissue chopper (Stoelting Co, Wood 
Dale, IL). Then, 5 slices were kept in inserts with collagen-coated transwell membranes 
(3.0 µm pore size; Corning, Lowell, MA). Inserts were placed in 6-well tissue culture plates 
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and incubated with BMSC conditioned culture medium or spinal cord slice culture medium 
containing 50 % MEM (Gibco), 25 % Hank’s balanced salt solution (Gibco), 25 % Heat 
Inactivated Horse Serum (Hyclone), 25 mM Hepes (J.T. Baker), 200 mM L-glutamine 
(Gibco), 3.5 g/L d-glucose, 100 U/ml penicillin, and 100 U/ml streptomycin. Slices were 
kept for five days in vitro (DIV) in a humidified chamber with 5 % CO2 at 37 °C. Medium 
was replaced every second day. After 5 DIV, cultures were fixed with 4 % 
paraformaldehyde in 0.1 M phosphate buffered saline (PBS) for two hours at room 
temperature. Cultures were then washed three times for 10 min with PBS and stored at 4 
˚C until imaging. Motoneuron survival in the slices was determined under the fluorescent 
microscope by quantifying YFP-positive motoneurons at 3 and 5 DIV. The numbers of 
slices per group were averaged.  
 
Spinal cord contusion and BMSC transplantation 
A total of 45 adult female Sprague Dawley rats (200-250 g; Charles River laboratories) 
were anaesthetized with an intraperitoneal injection of 60 mg/kg Ketamine (Butlerschein, 
Dublin, OH) and 0.5 mg/kg Dexdomitor (Pfizer, New York, NY)
3,38
. The backs were shaved 
and Lacrilube ophthalmic ointment was applied to the eyes to prevent drying during and 
after surgery. The skin and underlying muscles were incised and a laminectomy of the 
ninth thoracic (T9) vertebra was performed. The underlying T8 spinal cord was contused 
using the Infinite Horizon Impactor at an impact force of 200 kDyne. Subsequently, the 
muscles were sutured separately and the skin was closed with metal Michel wound clips 
(Butlerschein). Rats were given 1.5 mg/kg of Antisedan (Pfizer) subcutaneously to reverse 
Dexdomitor’s sedative effect, 6 mg/ml of Gentamicin (VWR, Radnor, PA) intramuscularly 
and 10 ml of Ringer’s solution subcutaneously (Butlerschein). Rats received daily injections 
of 5 ml Ringer’s subcutaneously, 6 mg/kg Gentamicin intramuscularly and 5 mg/kg of 
Rimadyl subcutaneously (Pfizer) until BMSC transplantation
3,38
. Bladders were manually 
emptied twice daily until reflex voiding recovered (± 2 weeks). 
Three days after the contusion, rats were anaesthetized as described above and the 
contused spinal cord was re-exposed. Next, 5 x 10
5
 BMSCs in DMEM or DMEM alone 
(volume = 5 µl; n = 10/group) was injected into the contusion epicenter using a glass 
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pulled needle on a Hamilton syringe held within a micromanipulator
3,38
. After injection, 
the needle was kept in place for 3 min and then retracted slowly over a 2 min period to 
prevent back leakage of the injectate. The muscles and skin were closed and the rats 
treated postoperatively as described above. Daily injections of Ringer’s and Rimadyl for 
three days and gentamicin for four days were given as described above
3,38
. There were 4 
experimental groups: BMSC, BMSC-BDNF, BMSC-BDNFshRNA, and DMEM. 
 
Histological and immunocytochemical procedures 
One week (n = 3 per group) or 4 weeks (n = 7 per group) after injection, rats were deeply 
anaesthetized with intraperitoneal injection of 90 mg/kg Ketamine (Butlerschein) and 0.75 
mg/kg of Dexdomitor and transcardially perfused with 250 ml of 0.1 M PBS followed by 
400 ml of 4% paraformaldehyde
3
. Spinal cords were dissected out, postfixed overnight in 
the same fixative, and then cryoprotected for 24 h in phosphate-buffered 30 % sucrose for 
24 h. Twelve mm long segments centered on the contusion epicenter were sectioned (20 
µm) on a Leica CM 1950 cryostat. Every twelfth section was stained with cresyl violet to 
reveal the cytoarchitecture. 
Sections were immuno-blocked and permeabilized in 5 % NGS and 0.03 % Triton for 30 
min at room temperature. Subsequently, sections were incubated with primary antibodies 
for 2 h at room temperature and then overnight at 4 ˚C. Used primary antibodies were 
rabbit polyclonal anti-glial fibrillary acidic protein (GFAP; 1:200; DAKO) to stain reactive 
astrocytes, mouse monoclonal rat endothelial cell antibody (RECA-1; 1:100; Abd Serotec 
MCA 970 GA) to stain blood vessels. After washing twice in PBS, sections were incubated 
with secondary antibody Alexa Fluor 594 or 488 at a concentration of 1:200 for two h at 
room temperature. Sections were stained with DAPI (2 µl/ml) for 3 min to stain nuclei, 
covered with glass slips in fluorescent mounting medium (Dako North America, Inc. 






Quantification of motoneurons and blood vessels 
The number of motoneurons (all cells > 25 µm) was determined in cresyl violet-stained 
sections. Motoneuron number was expressed as a percentage of the number of 
motoneurons in a comparable uninjured spinal cord segment.  
Blood vessels were quantified in RECA-1-stained sections using MATLAB® Software 
(MathWorks)
39
. In the three middle sections, at 20 X magnification, a sample (320 µm x 
420 µm) was taken in the gray matter about 600 µm laterocaudally to the injury epicenter 
and all RECA-1 positive structures were outlined
3
. The area fraction of the outlined 
structures was determined in each sample and averaged per rat. Averages for all rats per 
group were averaged.  
 
Assessment of GFP-positive BMSC number and spared tissue volume 
The number of GFP-positive BMSCs in the contusion was determined in DAPI-only stained 
sections using StereoInvestigator (MicroBrightField Inc., Colchester, Virginia, USA). In each 
section with GFP-positive cells, the transplanted area was outlined manually at 10 x 
magnification and covered with a 250 × 250 µm grid. At 60 X magnification with oil 
immersion, GFP-positive cells were marked using the optical fractionator with a 60 × 60 
µm counting frame
38
. Results were averaged per group and expressed as a percentage of 
the number of transplanted cells. 
The volume of spared nervous tissue was determined in cresyl violet-stained sections 
using the Cavalieri estimator function in StereoInvestigator® Software (MicroBrightField 
Inc). In each twelfth section the volume of spared tissue in a 3.4 mm long segment 
centered at the contusion epicenter was determined. Beyond the rostral and caudal 
borders of this segment cavities were absent. Within the analyzed segment, tissue was 
considered spared if it lacked cavities, areas with densely packed small cells resembling 
infiltrated neutrophils and lymphocytes, and neurons with darkly stained cytoplasmic Nissl 
bodies
38
. The Gundersen Coefficient of Error was < 0.05 for all measurements. The volume 
of spared tissue was expressed as a percentage of the average volume of a comparable 




For all results, one-way ANOVA with Tukey’s post-hoc analysis was used to compare 
differences among the experimental groups. Differences were accepted as statistical 
significant with p < 0.05. 
 
Ethics and surgical approval 
Rats used in this study were housed according to the National Institutes of Health and the 
United States Department of Agriculture guidelines. Rats were kept within a double-
barrier facility, air in the cages was continuously refreshed and water and food were 
available ad libitum. All animal procedures were approved by the Institutional Animal Care 
and Use Committee at the University of Pittsburgh. 
 
RESULTS 
In vitro characterization of modified BMSCs 
We characterized the transduced BMSCs in vitro and they were found to have stable GFP 
expression for at least seven passages. Transduction of BMSCs with LV-BDNF/GFP or LV-
BDNFshRNA/GFP did not change the presence of typical BMSC surface markers CD90 (Fig. 
1A, 1F, 1K, respectively) and CD105 (Fig. 1B, 1G, 1L, respectively) or the absence of the 
hematopoietic marker CD45 (Fig. 1E, 1J, 1O, respectively) compared to BMSCs transduced 
with LV-GFP
3,38
. BMSCs transduced with LV-BDNF exhibited an increase in staining for the 
BDNF receptors, TrkB (Fig. 1H) and P75 (Fig. 1I), while BMSCs transduced with LV-
BDNFshRNA exhibited a decrease in staining for these receptors (Fig. 1M, 1N) compared 
to BMSCs transduced with LV-GFP. ELISA was used to determine the effectiveness of the 
used LVs in P4 BMSCs. BMSCs transduced with LV-BDNF/GFP secreted 60.4 ± 8.3 pg/ml 
BDNF in 24 h, which was over six-fold higher than that secreted by BSMCs transduced with 
LV-GFP (9.4 ± 0.3 pg/ml/24 h) (Fig. 1P; p < 0.05). BMSCs transduced with LV-BDNFshRNA 
secreted an amount of BDNF below the linear range of the ELISA (7.8 pg/ml; ig. 1P). 
DMEM does not contain BDNF.  
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Fig. 1. Characterization of lentivirally modified BMSCs. Compared to control BMSCs (BMSC; A-E), lentiviral 
transduction of BMSCs with BDNF (BMSC-BDNF; F-J) or shRNA-BDNF (BMSC-shRNA-BDNF; K-O) does not change 
the expression of BMSC surface markers CD90 (A, F, K) and CD105 (B, G, L) or the absence of hematopoietic 
markers CD45 (E, J, O) but changes the expression of TrkB (C, H, M) and P75 (D, I, N). BMSC-BDNF exhibited 
increased staining for TrkB (H vs. C) and P75 (I vs. D) and BMSC-shRNA-BDNF exhibited decreased staining for 
TrkB (M vs. C) and P75 (N vs. D). Amounts of BDNF in conditioned medium of all types of modified BMSCs and 
DMEM (culture medium) was determined using ELISA (P). BDNF-hypersecreting BMSCs (BMSC-BDNF) secreted 
more than 6 times more BDNF than control BMSCs (BMSC). BDNF-hyposecreting BMSCs (shRNA-BDNF-BMSC) 
secreted amounts of BDNF undetectable for the ELISA. DMEM (Culture medium) also contained no detectable 
amounts of BDNF. Arrows indicates concentrations below the linear range of the ELISA (<7.8 pg/ml). Error bars 
display standard error of the mean (SEM). *p < 0.05.  
 
Increased BDNF sustains BMSC-mediated neuroprotection 
We used a spinal cord organotypic culture system to examine the neuroprotection 
potential of the modified BMSCs. Incubation with conditioned medium from cultured 
BMSCs transduced with LV-GFP, LV-BDNF, or LV-BDNFshRNA for 3 days resulted in a 58 % 
(M = 62.6 ± 6.4), 77 % (M = 70.1 ± 6.2), and 57 % (M = 62.1 ± 3.6) increase in YFP-positive 
motoneurons compared to incubation with spinal cord organotypic culture medium (Fig. 
2A; p < 0.05). This result showed that the BMSCs, regardless of their respective genetic 
modification, secreted trophic factors leading to a similar degree of motoneuron sparing 
and that BDNF is not a necessary factor for motoneuron protection in vitro. Interestingly, 
at 5 days in vitro the protective effect on motoneurons was sustained with conditioned 
medium from BDNF-hypersecreting BMSCs (M = 66.8 ± 5.6; 87 % increased over 
incubation with spinal cord organotypic culture medium) but not with conditioned 
medium from BDNF-hyposecreting BMSCs (M = 35.6 ± 4.4) or from control BMSCs (M = 
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49.8 ± 3.6) (Fig. 2B). Photographic examples are provided of spinal cord slices and YFP-
positive ventral motoneurons in conditioned medium from normal BMSCs (C and G, 
respectively), BDNF-hypersecreting BMSCs (D and H), BDNF-hyposecreting BMSCs (E and 
I), and with incubation in the defined spinal cord organotypic culture medium (Culture 
medium) (F and J). The data demonstrated that increased BDNF levels sustain spinal 
motoneuron sparing in vitro.  
 
 
Fig. 2. Sustained in vitro protection of ventral horn motor neurons by BMSC-BDNF. (A) At day three in vitro all 
types of BMSC conditioned medium  resulted in more live YFP-positive neurons in the ventral horn of 
organotypic spinal slices than unconditioned medium. At five days in vitro, conditioned medium from BDNF-
hypersecreting BMSCs (BMSC-BDNF), but not that from the other BMSC types, sustained motoneuron protection. 
(C-F) shows an example of a spinal cord slice and (G-J) shows YFP-positive ventral motoneurons in conditioned 
medium from normal BMSCs (C and G, respectively), BDNF-hypersecreting BMSCs (D and H), BDNF-hyposecreting 
BMSCs (E and I), and with incubation in the defined spinal cord organotypic culture medium (Culture medium) (F 




Fig. 3. BDNF-hypersecretion enhances motoneuron survival in a contused spinal cord. (A) Schematic 
representation of the quantification of ventral motoneurons in cresyl violet-stained sections of a 10-mm long 
spinal cord segment centered on the contusion epicenter. Motoneurons were found in the ventral spinal cord of 
rats injected with normal BMSCs (B), BDNF-hypersecreting BMSCs (C), BDNF-hyposecreting BMSCs (D), and 
DMEM (E). (F) Bar graph showing that 33% more motoneurons were spared in the group of rats that received 
BDNF-hypersecreting BMSCs compared to the knockdown and DMEM groups. Error bars display standard error 
of the mean (SEM). *p < 0.05. 
 
BDNF-hypersecretion enhanced motoneuron survival in a contused spinal cord 
Our in vitro data and previous studies showed that BDNF has protective effects on spinal 
motoneurons. We examined whether manipulation of BDNF secretion in a BMSC 
transplant would affect motoneuron survival in a 10-mm long spinal cord segment 
centered on the contusion epicenter (Fig. 3A). In rats with transplants of BMSCs 
transduced with LV-BDNF (Fig. 3B), 80.6 % ± 5.3 motoneurons relative to the number in a 
comparable uninjured spinal cord segment were present compared to 60.7 % ± 1.6 in rats 
with DMEM injections (Fig. 3E), which represents a 33 % increase in motoneuron number 
(p<0.05; Fig. 3F). Transplantation of BMSCs transduced with LV-GFP (Fig. 3C) or LV-
BDNFshRNA (Fig. 3D) did not result in a statistically significant increase in the number of 
motoneurons (M = 73.9 ± 5.6, M = 63.9 ± 4.3, respectively; Fig. 3F). 
 
BDNF-hypersecreting BMSCs augment BMSC-mediated blood vessel protection 
Previously, we have demonstrated that BMSC transplants results in increased blood vessel 
numbers in a contused spinal cord
3
. Here, we examined the role of BDNF in this protective 
effect by determining the density of blood vessels near the contusion (Fig. 4A). Blood 
vessels were present in rats with BMSCs transduced with LV-GFP (Fig. 4B), LV-BDNF (Fig. 
4C), LV-BDNFshRNA (Fig. 4D), and in rats with DMEM injections (Fig. 4E). Quantification  
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Fig. 4. BDNF-hypersecretion augment BMSC-mediated blood vessel sparing in a contused spinal cord. (A) 
Schematic of the contusion injury with gray matter and location where blood vessel density was determined. 
RECA-1-positive blood vessels were found in gray matter near the contusion in rats with normal BMSCs (B), 
BDNF-hypersecreting BMSCs (C), BDNF-hyposecreting BMSCs (D), and DMEM (E). (F) Bar graph showing that rats 
with BDNF-hypersecreting BMSCs had a 6-fold increase and rats with an injection of normal BMSCs had a 4-fold 
increase in blood vessel density compared to DMEM. Rats that received BDNF-hyposecreting BMSCs had a lower 
density of blood vessels compared to rats with normal BMSCs. Dotted line in F indicates mean blood vessel 
density in uninjured controls. Error bars display standard error of the mean (SEM). *p < 0.05 compared to DMEM 
and †p < 0.05 compared to BMSC.  
 
revealed a significant six-fold increase (p < 0.05) in blood vessel density in rats with BDNF-
hypersecreting BMSCs compared to rats with DMEM injections (Fig. 4F).  Rats with BMSCs 
transduced with LV-GFP had a significant four-fold increase in blood vessel density 
compared with rats with DMEM injections (Fig. 4F). Overexpressing BDNF in a BMSC 
transplant resulted in a 35 % increase and silencing BDNF expression in a 76 % decrease in 
blood vessel density compared to normal BMSCs (Fig. 4F). 
 
Tissue sparing 4 weeks after BMSC transplantation 
Previous research showed that intraspinal BMSC transplants result in larger volumes of 
spared nervous tissue
3,38
. Here, we examined the role of BDNF in BMSC-mediated 
neuroprotection in the contused spinal cord. At four weeks post-injection, the volume of 
spared tissue in rats that received BMSCs transduced with LV-GFP or LV-BDNF was 68 % 
larger (p < 0.05) in both groups compared to that in rats with DMEM injections (Fig. 5). 
Spared tissue volume in rats with BDNF-hyposecreting BMSCs was similar as in rats with 
DMEM injection (Fig. 5). These results show that BDNF is necessary for BMSC-mediated 




Fig. 5. Tissue sparing 4 weeks after BMSC transplantation. Four weeks after transplantation, a protective effect of 
BMSCs on nervous tissue is present. The bar graph shows that transplantation of normal BMSCs (BMSC) and 
BDNF-hypersecreting BMSCs (BMSC-BDNF) resulted in increased volumes of spared tissue compared with rats 
with DMEM or BDNF-hyposecreting BMSCs. The latter group was not significantly different from the DMEM 
group. Error bars display standard error of the mean (SEM). *p < 0.05. 
 
BDNF-hyposecretion affects BMSC survival in a spinal cord contusion 
Survival of a BMSC transplant in damaged nervous tissue is limited
38
. We examined 
whether increased or decreased BDNF secretion would affect BMSC survival in a contusion 
environment. One week after transplantation into a three-day old spinal cord contusion, 
transplanted BMSCs transduced with LV-GFP (Fig. 6A) or LV-BDNF (Fig. 6B) appeared to be 
mostly spindle-shaped, which was in agreement with our previous study
38
. Stereology-
based quantification showed that 13.7 ± 2.2 % of the transplanted BMSCs transduced with 
LV-GFP and 17.2 ± 4.9 % of BMSCs transduced with LV-GFP were present in the contusion 
(Fig. 6D). Transplanted BMSCs transduced with LV-BDNFshRNA were not found in the 
contusion (Fig. 6C). The data show that BDNF is necessary for BMSC survival in a spinal 




Fig. 6. BDNF-hyposecretion affects BMSC survival in a contusion. One week after transplantation into the 
contused spinal cord, BMSCs appeared mostly as spindle-shaped cells in transplants of normal BMSCs (BMSC) 
and of BDNF-hypersecreting BMSCs (BMSC-BDNF) (A,B). BDNF-hyposecreting BMSCs were not detected in the 
contusion (C). Quantification revealed similar numbers in transplants of normal and BDNF-hypersecreting BMSCs 
(D). Error bars display standard error of the mean (SEM). 
 
DISCUSSION 
The repair-supporting effects of BMSC transplants in the injured spinal cord
3-9
 are thought 
to result from paracrine actions by secreted trophic factors
9-16
. We used gene therapy to 
manipulate BDNF production by BMSCs and assess its role in BMSC-mediated 
neuroprotection. Our experiments revealed that in vitro increased BDNF amounts 
sustained motoneuron protection. In the contused spinal cord, BDNF overexpression by 
grafted BMSCs protected motoneurons and blood vessels; spared tissue volume was 
unaffected. The data suggest that enhancing BDNF levels in BMSC transplants elicit 
neuronal and vascular effects that may be beneficial for recovery after spinal cord injury.  
87 
With an organotypic culture system we showed that motoneuron survival in spinal cord 
slices was similar in conditioned medium with normal, increased, or decreased amounts of 
BDNF. This finding indicated that BDNF is not necessary for in vitro spinal motoneuron 
survival and that other trophic factors secreted by BMSCs are sufficient for this 
neuroprotective effect. After the first days in culture, motoneuron survival was only 
sustained with increased BDNF amounts. Thus increased BDNF is vital to maintain the 
motoneuron survival-promoting effects exerted by the trophic molecules secreted by 





Transplantation of BDNF-hypersecreting BMSCs enhanced motoneuron survival in the 
ventral gray matter in the contused adult rat spinal cord. This finding is in agreement with 
our in vitro observation that conditioned medium from BDNF-hypersecreting BMSCs 
promoted and sustained motoneuron survival in spinal cord organotypic cultures. BDNF is 
known to exert neurotrophic actions on neurons
9-16
 and treatment of injured spinal cord 
with BDNF
22-25
 or with BDNF-hypersecreting cells promotes neuron survival
26-28,41-44
. In our 
spinal cord organotypic culture, BDNF was found not to be a necessary factor for 
motoneuron sparing; other BMSC-derived factors were sufficient. We were unable to 
verify whether this finding would translate to the in vivo spinal cord injury model because 
silencing BDNF production in BMSCs resulted in rapid loss of transplanted BMSCs. 
 
The finding that survival of BMSCs with decreased BDNF was inferior to that of BMSCs 
with normal or increased BDNF in a contusion environment is intriguing. To our 
knowledge, this is the first demonstration of transplantation of BMSCs with silenced BDNF 
production into the injured spinal cord. In culture, we observed no difference in survival of 
any of the differently modified BMSCs used in this study. Also, BDNF hypersecretion did 
not enhance BMSC survival in vitro or in vivo. How can we explain the decrease in BMSC 
transplant survival in the absence of BDNF? It is possible that grafted BMSCs are protected 
by BDNF from apoptotic death
21,40
 due to injury-related events including oxidative stress, 
hypoxia, and/or transplant preparation-related events such as detachment which induces 
88 
anoikis. Possibly, the observed lower expression of the BDNF receptors, TrkB and P75 in 
BDNF-hyposecreting BMSCs contributed to the lower survival in the contusion. In culture, 
injury-related events are absent and cells are attached; thus, BDNF would not be required 
for their protection. Further research is needed to elucidate the role of BDNF in BMSC 
transplant survival in a spinal cord contusion. 
 
In the contused spinal cord with a transplant of BDNF-hypersecreting BMSCs the volume 
of spared nervous tissue was similar as with normal BMSCs. Our finding that a transplant 
of normal BMSCs resulted in improved tissue sparing corroborated with data from our 
previous studies
3,38
 as well as that from other groups
4-6
. The lack of additional nervous 
tissue sparing with increased BDNF was also shown with a complete spinal cord 
transection
25
 but not in a partial, dorsal column, transection
44
. Possibly, the severity of the 
injury is a determinant in BDNF-mediated tissue sparing. As discussed above, early death 
of BMSCs with decreased BDNF production prevented determining whether BDNF is 
necessary for BMSC-mediated tissue sparing.  
 
A transplant of BMSCs with increased BDNF production significantly augmented BMSC-
mediated increases in blood vessel density near the injury epicenter. Previously, we 
showed that BMSC transplants resulted in increased vascularization in the contused spinal 
cord
3
. Here, we extend this observation and show that BMSC-secreted BDNF possibly 
plays a role to elicit this effect. Other studies have also implicated BDNF in vascular events 
in the injured nervous tissue
25,29-33
, possibly through upregulation of vascular endothelial 
growth factor
30
. It is possible that the effects of increased BDNF on motoneuron sparing 
and blood vessel sparing as we demonstrate in our study are related. Enhancing blood 
vessel number through angiogenic/angioprotective effects may have resulted in 
neuroprotection
34-36
. Future research will need to elucidate the interplay between BDNF-
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We tested whether reducing macrophage infiltration would improve the survival of 
allogeneic bone marrow stromal cells (BMSC) transplanted in the contused adult rat 
thoracic spinal cord. Treatment with cyclosporine, minocycline, or methylprednisolone all 
resulted in a significant decrease in macrophage infiltration at 3 days postinjury. However, 
when BMSC were injected at that time point, survival 7 days later was similar between 
treatment groups and saline-injected controls. In fact, we found that the presence of 




A contusive spinal cord injury causes immediate death of neural cells and disruption of 
axon circuits
1
. The number of macrophages in the injury site rapidly increases over the 
ensuing days and contribute to further destruction of local nervous tissue
2
. There is no 
therapy available that effectively improves function after spinal cord injury. 
Transplantation of bone marrow stromal cells (BMSC) has been explored for spinal cord 
repair
3
. In different model systems, BMSC transplantation resulted in tissue sparing and, in 
some cases, improved motor function
4-7
. These results warrant further investigation of 
BMSC for nervous system repair. Survival of allogeneic BMSC transplanted into the 
damaged spinal cord is low
4,7,8
. Several studies have pointed at a role of macrophages in 
the loss of BMSC after injection into the injured nervous system
8,9
. Thus, we reasoned that 
a reduction in macrophage number in an injury site would increase the survival of 
transplanted BMSC. Cyclosporine A (CsA), minocycline (MC), and methylprednisolone (MP) 
treatment decreases macrophage infiltration into a spinal cord lesion
8,10-13
. This study 
focuses on the efficacy of these three drugs to reduce macrophage infiltration and 
whether this would result in increased survival of subsequently transplanted BMSC. 
 
METHODS 
Spinal cord contusion and postsurgery care  
Adult female Sprague–Dawley rats (n=76, 200–230 g; Harlan, Indianapolis, Indiana, USA) 
were anaesthetized with an intraperitoneal injection of 60 mg/kg of ketamine HCl 
(Phoenix Pharmaceuticals, St Joseph, Maryland, USA) and 0.4 mg/kg medetomidine 
(Domitor, an a-2- adrenergic agonist; Orion Corp., Espoo, Finland). The 10th thoracic spinal 
cord segment was exposed and contused using the Infinite Horizon Impactor (Precision 
System & Instrumentation, Lexington, Kentucky, USA) at a force of 200 kDyn (Fig. 1a). 
Consistency between animals was guaranteed by registering the impact force and spinal 
cord displacement. The wound was closed and the rats were given antisedan (atipamezole 
hydrochloride; 1.25 mg/kg, intramuscular), an a-2-adrenergic antagonist that reverses  
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Fig. 1. Schematic representation of the experiments and BMSC harvest and transduction. A. Rats were contused 
at the 10th thoracic spinal cord segment and then divided into 4 groups that received CsA, MC, MP or saline. B. 
BMSC were harvested, transduced to express GFP using lentiviral vectors, and grown in DMEM. C. GFP-
expressing BMSC in a passage 3 culture which were used for transplantation into the epicenter of the 3-day old 
contusion. Abbreviations: BMSC, bone marrow stromal cells; CsA, cyclosporine A; ip, intraperitoneal; MC, 
minocylcine; MP, methylprednisolone; sc, subcutaneous. Bar in C represents 10 µm. 
 
sedative and analgesic effects of medetomidine. All surgical procedures were performed 





Contused rats were divided into four groups that received CsA, MC, MP, or saline (n=18 
each; Fig. 1a) starting 5 min after the contusion. All injections were performed by the 
same investigator. CsA (Bedford Labs, Bedford, Ohio, USA) was administered 
subcutaneously once per day at a dose of 30 mg/kg for the first three days and 15 mg/kg 
for the next 7 days
8
. MC (Sigma-Aldrich, St Louis, Missouri, USA) was administered 
intraperitoneally at a dose of 50 mg/kg twice a day for the first two days
12
. MP (Sigma-
Aldrich) was administered intraperitoneally once at a dose of 30 mg/kg
10
. Saline was given 
to controls following the same regime as for MP.  
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Bone marrow stromal cell culture and lentiviral transduction  
BMSC were obtained from femurs of adult female Sprague-Dawley rats (n=4) as described 
earlier
7,14
 (Fig. 1b). BMSC at passage 0 were transduced overnight using lentiviral vectors 
encoding for green fluorescent protein (LV-GFP) at an MOI of 150
7,15
. Transduced BMSC 
were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum at 
371C/5% CO2. BMSC from the third passage (Fig. 1c) were used for the transplantation 
experiments. The transduction rate of the BMSC was determined using a 
FACScan/FACSorter [Becton Dickinson Immunocytometry Systems (BDIS) Biosciences, San 
Jose, California, USA]. The number of viable GFP-positive cells relative to the total number 
of cells was 63%.  
 
Transplantation of bone marrow stromal cells  
At 3 days after injury, 24 rats (six rats from each group) were anaesthetized with 
intraperitoneal injections of 60mg/kg of ketamine HCl (Phoenix Pharmaceuticals) and 
0.4mg/kg of medetomidine (Domitor; Orion Corporation). The 10th thoracic spinal cord 
segment was exposed and 5 ml Dulbecco’s modified Eagle’s medium with 1 x 10
6
 BMSC 
(Fig. 1a) was injected into the contusion epicenter
14
. Four additionally-contused rats were 
similarly injected and perfused with fixative (see below) 15min later. These rats were used 
to determine the number of BMSC in the contusion at 15min postinjection. All BMSC 
injections were given by the same investigator. After the injections, the rats were 




General histology  
Three days (n=24) and 10 days (n=48) after injury, rats were anaesthetized with an 
intraperitoneal injection of 90 mg/kg of ketamine HCl (Phoenix Pharmaceuticals) and 0.6 
mg/kg of meditomidine (Orion Corporation). After deep sedation was confirmed, 0.1 ml 
heparine (500 IU; Henry Schein, Melville, New York, USA) was injected into the left 
ventricle of the heart. Then, 500 ml saline followed by 500 ml ice-cold 4% 
paraformaldehyde in phosphate buffer (PB; 0.1 M, pH 7.4) was pumped through the 
vascular system. Spinal cords were removed without damaging the anatomical integrity, 
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postfixed for 24 h in the same fixative, and transferred to 30% sucrose in phosphate-
buffered saline (PBS; 0.1 M, pH 7.4) for 48 h. A 12-mm-long spinal cord segment centered 
at the contusion was cut into 20-mm-thick horizontal cryostat sections, which were 
mounted on glass slides.  
 
Immunocytochemical procedures  
For characterization of the BMSC, eight-well chamber glass slides (BD Falcon; BD 
Biosciences, Bedford, Massachusetts, USA) were coated with 100 ml/ml poly- D-lysine for 
1 h at room temperature. After washing 2 x 5 min with double-distilled water, 3000 BMSC 
in 250 ml D-10 medium were plated per well. After 2 days at 37 °C/ 5% CO2 the cultures 
were washed 3 x 5 min with PBS and fixed with 4% paraformaldehyde in PB (10 min, room 
temperature. Next, the cultures were washed 5 x 5 min with PBS, incubated with 5% 
normal goat serum (NGS) in PBS for 30 min, and then incubated overnight at 4 °C with 
antibodies against CD90 (1 : 100; Immunotech, Brussels, Belgium), CD105 (1 : 100; N1G1, 
Becton Dickenson), CD34 (1 : 100; 8G12 clone IgG1, Becton Dickenson), CD45 (1 : 100; 
H130 clone IgG1, Becton Dickenson), and HLA-DR (1 : 100; Dako, Clostrup, Denmark) 
diluted in PB with 5% NGS. Some cultures were incubated with PB with 5% NGS only and 
served as negative (no primary antibody) controls to exclude a a false-positive outcome. 
Next, cultures were washed 3 x 5 min with PB and then incubated with goat-anti-mouse 
IgG-Alexa 594 (1:500 in PB; Molecular Probes, Carlsbad, CA) for 2 h at room temperature. 
Afterwards, cultures were washed 3 x 5 min with PB and covered with a glass slip with 
Vectashield and DAPI (Vector Laboratories, Inc., Burlingame, CA). The slides were 
examined and images were taken with an Olympus Fluoview FV1000 confocal microscope. 
 
For immunostaining of activated macrophages, every 10th cryostat section was pre-
incubated at room temperature for 30 min in 5 % NGS and 0.3 % Triton X-100 in 0.01 M 
PBS (pH 7.4) and then incubated with antibodies against ED1 (1:200; Serotec, Raleigh, NC) 
in 5 % NGS for 2 h at room temperature followed by overnight incubation at 4 °C. After 
washing 3 x 5 min with PBS, sections were incubated with goat anti-mouse Alexa 594 
antibodies (1:200; Molecular Probes) in PBS (0.01 M; pH 7.4) at room temperature for 2 h. 
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The sections were then washed and covered with a glass slip in Vectashield with DAPI 
(Vector Laboratories, Inc.). The coverslips were sealed with nail polish. All sections were 
stored at -20 °C until analysis. 
 
Quantitative assessments 
For analysis of GFP-positive BMSC, every 10th cryostat section was covered with a glass 
slip with Vectashield mounting medium with DAPI (Vector Laboratories, Inc). 
Stereoinvestigator (MicroBrightField Inc., Colchester, VA, USA) was used to determine the 
numbers of surviving BMSC in the contusion
16
. The sections were 200 mm apart spanning 
the width of the spinal cord. In every section containing GFP positive cells, the 
transplanted area was outlined manually at 4 X magnification and covered by a 250 x 250 
μm grid. At 60 X magnification with oil immersion, GFP-positive cells with a discernable 
DAPI-positive nucleus were marked using the optical fractionator with a 60 x 60 μm 
counting frame. Numbers were corrected for the 63 % transduction rate of the BMSC with 
LV-GFP. For each of the groups, BMSC survival was calculated as the number of BMSC 
relative to the number of BMSC at 15 min after transplantation (which was 168159 ± 
31129; SEM, n=4). The effect of treatment on BMSC survival was assessed by expressing 
BMSC survival for each group as a percentage of that in controls. For analysis of 
macrophages we employed a method described by Hayashi and colleagues
17
. This method 
uses three sections per rat for examination: one section through the center of the 
contusion/transplant (with the densest cellular staining), and sections 200 µm dorsal and 
ventral to the center. The area fraction of staining in these sections was determined using 
SlideBook 4.1.0.12 (Intelligent Imaging Innovations, Inc, Santa Monica, CA, USA) and 
expressed as a percentage of that in control animals.  
 
Statistical analysis 
Sigmastat® (Systat Software, Inc., San Jose, CA, USA) was used for statistical analyses using 




Ethics and surgical approval 
All rats used in this study were housed according to the guidelines of the National Institute 
of Health and United States Department of Agriculture. The described animal procedures 




Characterization of BMSC in vitro 
Cultured GFP-positive cells expressed CD90 (Fig. 2a) and CD105 (Fig. 2b). These two 
extracellular molecules are both well-known BMSC markers
18,19
. None of the cells 
expressed the blood cell markers, CD34 (Fig. 2c) and CD45 or the immune cell marker, 
HLA-DR. No staining was visible if the primary antibody was omitted. The data characterize 
the cells used for transplantation as BMSC.  
 
 
Fig. 3. Characterization of bone marrow stromal cells (BMSC) in vitro. Cultured cells expressed the BMSC 
markers, CD90 (A) and CD105(B), but not the blood cell marker, CD34 (C). Scale bar =10 mm. 
 
CsA, MC, and MP reduce macrophage infiltration into the spinal cord contusion 
Microscopic analysis of macrophage presence in the contusion revealed high numbers in 
controls (Fig. 3a) compared to treated rats (Fig. 3b) at 3 days after injury. The numbers 
appeared increased in treated rats at 10 days (Fig. 3c) compared to 3 days (Fig. 3b) after 
contusion. Quantitative analysis demonstrated that at three days post-injury, relative to 
controls, macrophage infiltration was 46 ± 10 % with CsA-, 47 ± 3 % with MC-, and 63 ± 3 
% with MP-treatment (Fig. 3d). ANOVA revealed that the number for each of the 
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treatment groups was significantly smaller (p<0.001) than that for controls. Thus 
treatment-induced reduction was 54 % with CsA, 53 % with MC, and 37 % with MP 
compared to controls. Treatment-induced reduction was not significantly different from 
controls at ten days post-injury (Fig. 3d). These results showed that all three drugs when 
administered following the treatment regime described above reduced macrophage 
infiltration into the adult rat spinal cord contusion at three days post-injury.  
 
BMSC survival in contusion is not affected by CsA, MC, or MP treatment 
BMSC were present in the contusion at seven days post-injection (Fig. 4a). Quantitative 
analysis revealed that BMSC survival in the contusion at seven days post-injection was 27 
± 4 % with CsA, 24 ± 4 % with MC, and 33 ± 2 % with MP treated rats. In saline-injected 
control rats, BMSC survival was 21 ± 7 %. To assess the effects of treatment, we expressed 
BMSC survival in each treatment group relative to that in the control group (Fig. 4b). We 
found that BMSC survival was 126 ± 17 % with CsA, 111 ± 19 % with MC, and 155 ± 12 % 
with MP treated rats relative to control rats (Fig. 4b). ANOVA revealed no difference in 
BMSC survival between treatment and control groups (p=0.16). 
 
 
Fig. 4. Cyclosporine A (CsA), minocycline (MC), and methylprednisolone (MP) treatment reduced macrophage 
infiltration into the contusion. Photomicrographs of ED-1-positive cells in control rats (A) and CsA-treated rats (b) 
at 3 days postcontusion and in CsA-treated rats at 10 days postcontusion (B). In panel (C) the more intense 
staining was found associated with cellular debris. (D) Bar graph shows that at 3 days postinjury (open bars) 
relative to controls (Con), macrophages infiltration in the contusion was decreased significantly with CsA, MC, 
and MP treatment. At 10 days postinjury (solid bars), the decrease in macrophage presence in the contusion of 
treated rats was not statistically different from that in Con. *Significant difference between treated and Con 
groups at 3 days postinjury with P<0.001. 
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BMSC presence initiates macrophage infiltration into the spinal cord contusion. 
We assessed the effect of a BMSC transplant on macrophage presence in the contusion at 
ten days post-injury relative to that at three days post-injury. With a BMSC transplant, 
macrophage infiltration relative to controls was 2.4 fold in CsA- and MP-treated rats, and 
6.9 fold in MC-treated rats. These differences were statistically significant (p<0.001). In the 
absence of a BMSC transplant, macrophage presence in treated rats relative to controls 
was unchanged. Our data demonstrated that the presence of a BMSC transplant 
significantly increased macrophage infiltration into the contused adult rat spinal cord.  
 
 
Fig. 5. Cyclosporine A (CsA), minocycline (MC), and methylprednisolone (MP) treatment did not improve bone 
marrow stromal cell (BMSC) survival. (a) Photomicrograph of green fluorescent protein-positive cells within the 
contusion at 7 days postinjection. (b) Bar graph showing BMSC survival relative to controls (Con). The differences 
were not statistically different, although there was a trend towards higher numbers in CsA-treated rats. 
 
DISCUSSION 
Quantitative investigations have demonstrated that survival of BMSC transplanted into 
the contused adult rat spinal cord is low
4,7
. Previously, it was proposed that macrophages 
which are naturally present within an injury site are involved in the loss of BMSC 
transplanted into the central nervous system
9
. Our present results showed that a 
decreased presence of activated macrophages at the time of BMSC injection (three days 
post-injury) does not increase survival of grafted BMSC. It is possible that our treatment 
regimens failed to lower macrophage infiltration to a level where BMSC survival would 
have been improved. The maximum reduction which was achieved here was 54%. Because 
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macrophage invasion into a spinal cord injury site is typically large
1,2,11
, this reduction may 
still leave many macrophages that could potentially contribute to BMSC loss. An additional 
observation is that the treatment effect which was present at three days post-injury was 
not significant at ten days post-injury. Although we used treatment protocols known to 
effectively reduce the presence of macrophages
8,10-13
 they might not have been effective 
enough for sufficient and prolonged reduction of macrophages.  
 
An alternative explanation for the observed lack of improved BMSC survival would be that 
any treatment-induced reduction in macrophage presence was masked by a subsequent 
increase in macrophage infiltration due to the introduction of BMSC into the environment. 
This notion is supported by our data because in animals with a BMSC transplant we found 
that macrophage infiltration was drastically increased. It is likely that these extra 
macrophages have exacerbated the loss of BMSC
20
. It is important to keep in mind that 
other factors than invaded macrophages are most likely also involved in transplanted 




Previously, it was reported that BMSC are hypo-immunogenic; they suppress the 
proliferation and function of T-cells, B-cells, natural killer cells, and dendritic cells
22
. 
However, these publications did not investigate possible effects of BMSC on macrophage 
invasion. It is possible that the immunosuppressive properties of BMSC affect only the 
adaptive immunity due to the low expression level of human leukocyte antigen (HLA) 
major histocompatibility (MHC) class I and the absence of co-stimulatory molecules
22
. This 
would explain why the recruitment of macrophages (acquired immunity) would not be 
affected by BMSC. 
 
Lowering the number of macrophages in the injured spinal cord needs to be addressed 
with caution. It is well known that macrophages can support spinal cord repair by 
promoting axon regeneration and myelination which may be accompanied by improved 
function
23,24
. These constructive effects occur while macrophages also exert destructive 
effects such as neural cell death
25
. Because of this dual role, decreasing the number of 
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macrophages within a spinal cord injury could lead simultaneously to beneficial and 
detrimental effects
24
. Thus it is important to aim for a reduction in macrophages that 
would not jeopardize their positive contributions to spinal cord repair.  
 
CONCLUSION 
After spinal cord contusive injury, concurrent macrophage reducing treatments did not 
improve survival of transplanted BMSC. The presence of BMSC in the contusion site 
resulted in a four-fold increase in macrophage numbers.  
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Cell therapy for nervous tissue repair is limited by low transplant survival. We investigated 
the effects of a polyurethane-based reverse thermal gel, poly(ethylene glycol)-poly(serinol 
hexamethylene urethane) (ESHU) on bone marrow stromal cell (BMSC) transplant survival 
and repair using a rat model of spinal cord contusion. Transplantation of BMSCs in ESHU at 
three days post-contusion resulted in a 3.5-fold increase in BMSC survival at one week 
post-injury and a 66% increase in spared nervous tissue volume at four weeks post-injury. 
These improvements were accompanied by enhanced hindlimb motor and sensorimotor 
recovery. In vitro, we found that ESHU protected BMSCs from hydrogen peroxide-
mediated death, resulting in a four-fold increase in BMSC survival with two-fold fewer 
BMSCs expressing the apoptosis marker, caspase 3 and the DNA oxidation marker, 8-Oxo-
deoxyguanosine. We argue that ESHU protected BMSCs transplanted is a spinal cord 
contusion from death thereby augmenting their effects on neuroprotection leading to 
improved behavioral restoration. The data show that the repair effects of intraneural 
BMSC transplants depend on the degree of their survival and may have a widespread 




Cell therapy is promising for repair of the damaged nervous system
1-3
. Bone marrow 
stromal cells (BMSCs) are candidate cells for such therapies because of their repair 
proficiency and relative accessibility
4-7
. BMSCs support repair of a myriad of other ailments 
including cardiomyopathy, muscle dystrophy, and wound healing
8-10
. Intraneural BMSC 
transplants are thought to elicit repair through paracrine effects
11-14
. However, these 
effects are likely limited due to low transplant survival in damaged nervous tissue
15-18
. 
Cell transplants may be lost due to various events including inflammation
19
  and oxidative 
stress
20-24
, which are initiated rapidly after injury. Thus, measures to protect cell 
transplants against these death-mediating mechanisms may increase transplant survival 
and potentially improve their reparative effects. One strategy to improve transplanted cell 
survival is by using the synthetic poly(ethylene glycol)-poly(serinol hexamethylene 
urethane) or ESHU, which is a reverse thermal gel with good biocompatibility and 
degradability
25,26
. ESHU is a copolymer with two hydrophilic poly(ethylene glycol) blocks 
flanking a hydrophobic poly(serinol hexamethylene urethane) block
25
. The presence of 
polyurethane
28,29
 may provide ESHU with antioxidant capacity. ESHU dissolves in water 
and undergoes phase transition with increasing temperatures to form a physical gel at 
37C
25
, which makes it especially practical for treatment of closed injuries
30
.  
ESHU was shown to have good biocompatibility with nervous tissue in the ocular 
system
26,27
. A beneficial feature of ESHU is that the repeating units of the polymer contain 
protected amine groups providing an easy path to functionalization using biomolecules or 
other signaling molecules that can offer enhanced bioactivity of the gel in vivo. One 
example is to functionalize ESHU through these amine groups with the pentapeptide, 
IKVAV, which in pilot experiments was shown to produce a neural interface similar to 
laminin.  
We hypothesized that ESHU protects intraneural BMSC transplants from death leading to 
improved repair. This premise was tested in vivo using an adult rat model of spinal cord 
contusion
7,15,16
 assessing BMSC transplant survival, inflammation, anatomical restoration, 
and functional recovery and in vitro using BMSC cultures determining the effects of ESHU 
on survival of BMSCs under oxidative stress. 
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MATERIALS AND METHODS 
Ethics and surgical approval  
Before and after surgery, rats were housed following guidelines of the National Institutes 
of Health and the United States Department of Agriculture. The rats were kept within a 
double-barrier facility in standard rat cages with continuous supply of fresh air, water, and 
food. All procedures were approved by the Institutional Animal Care and Use Committee 
at the University of Pittsburgh. 
 
Transplant preparation 
We harvested BMSCs from femurs of female adult Sprague Dawley rats according to a 
previously described protocol (Fig. 1a)
7,15,31
. Isolated cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma-Aldrich, Allentown, PA, USA) with 10% fetal 
bovine serum (Mediatech, Manassas, VA, USA) and 1% penicillin/streptomycin (Invitrogen, 
Grand Island, NY, USA). To enable detection after transplantation, first passage cells were 
transduced to express green fluorescent protein (GFP) using lentiviral vectors (Fig. 
1a’)
7,15,31
. Fourth passage cells positive for the BMSC markers, CD90 and CD105 and 
negative for blood cell markers, CD34, CD45 and HLA-DR
16,32,33 




The preparation of ESHU (Fig. 1b) was previously described
25
. In brief, polyurethane blocks 
were synthesized by melting N-BOC-serinol (Sigma-Aldrich) under nitrogen and slowly 
adding hexamethylene diisocyanate (HDI; TCI America, Wellesley Hills, MA, USA) to initiate 
polymerization via urethane bonds. Both ends of polyurethane were capped with an 
isocyanate group using additional HDI and then dissolved in anhydrous 
dimethylformamide. Diethyl ether (Fisher Scientific, Pittsburgh, PA, USA) was used to 
precipitate out the polymer and remove unreacted hexamethylene diisocyanate. 
Polyethylene glycol (Alfa Aesar, Ward Hill, MA, USA) was coupled onto the polyurethane 
blocks under nitrogen, dissolved in dimethylformamide (EMD, Gibbstown, NJ, USA), and 
precipitated in and washed with diethyl ether. For purification, ESHU was dissolved in 
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water and dialyzed (3500 MWCO) for 48h and finally freeze-dried. In our experiments, a 
16% w/v ESHU solution in phosphate-buffered saline (PBS; pH 7.4) was prepared and 
sterile-filtered before use. 
 
Surgical procedures  
A model of adult rat spinal cord contusion
34,35
 was used to test our hypothesis. Female 
adult Sprague Dawley rats (200 g, n=80; Charles Rivers Laboratory, Wilmington, MA, USA) 
were anaesthetized using intraperitoneal injection Ketamine (60 mg/ml; Butlerschein, 
Dublin, OH, USA) and Dexdomitor (0.5 mg/kg; Pfizer, New York, NY, USA)
7,15
. The tenth 
thoracic spinal cord segment was contused using a force of 200 kDyne (Infinite Horizon IH-
0400 impactor; Precision Systems and Instrumentation, LLC, Versailles, KY, USA)
7,15,36
. The 
wound site was rinsed with sterile PBS with 0.1% gentamicin (VWR, Radnor, PA), the 
muscles were sutured in layers, and the skin was closed with Michel wound clips (Fine 
Science Tools, Foster City, CA, USA). All rats included in the studies had an impact within 
5% of the intended force resulting in a 0.9-1.8 mm spinal cord compression and a Basso-
Beattie-Bresnahan (BBB)
37,38
 score ≤ 1 at day 1 and ≤ 5 at day 3 post-impact. Three days 
post-injury, rats were sedated and injected into the contusion
7,15,16
 with 5 µl ESHU or PBS 
with 5x105 BMSCs, or ESHU or PBS only. 
 
Post-surgery procedures  
Antisedan (1.5 mg/kg; Pfizer) was injected subcutaneously to reverse the effects of 
Dexdomitor
7,15
. An intramuscular injection of gentamicin (6mg/kg; VWR), a subcutaneous 
injection of Rimadyl (5 mg/kg; Pfizer), and a subcutaneous injection of Ringer’s solution 
(10 ml on surgery day, 5 ml thereafter; Butlerschein) were administered daily for the first 
three days post-injury
7,15
. After the intraspinal injection at three days post-injury, the rats 
received gentamicin for four days and Ringer’s and Rimadyl for three days
7,15
. Bladders 
were manually emptied twice daily until reflex voiding occurred. Rats were monitored 
daily throughout the experiments. Rats were fixed at 15 min, one, four, or six weeks after 
injection. All rats survived without requiring pain or distress treatment. 
 
110 
Motor function assessment  
Overground walking ability was assessed using the BBB test
37,38
 weekly for six weeks post-
injection (n = 10/group). Rats were tested for 4 min by two testers unaware of the 
treatments. Rats were familiarized with the open field and baseline values were 
determined before surgery. Scores were averaged per experimental group. Higher motor 
functions were assessed at six weeks post-injury using the BBB sub-score
39,40
 as previously 
described (n = 10/group)
7
. Scores were averaged per experimental group. Sensorimotor 
function of the hind limbs was assessed before (baseline) and at six weeks post-injection 
using horizontal ladder walking (n = 10/group)
7,41,42
. Slips of the foot and part of lower leg 
and slips of the full leg were counted and expressed as a percentage of the total number 
of steps. Scores were averaged per experimental group. 
 
Histological procedures 
Rats were anaesthetized and transcardially perfused with 300 ml PBS followed by 400 ml 4 
% paraformaldehyde (Sigma-Aldrich) in PBS. Spinal cords were dissected, post-fixed 
overnight in the same fixative, and transferred to 30% sucrose (Fisher Scientific) in PBS for 
48 h. A 12 mm-long spinal cord segment centered at the injury epicenter was cut in 20 
μm-thick horizontal cryostat sections (CM 1950; Leica Biosystems, Buffalo Grove, IL, USA). 
Every twelfth section was stained with cresyl violet (0.5 %; Sigma-Aldrich) for 
cytoarchitecture analysis and spared tissue volume assessment. Other section series were 
used for immunocytochemistry. Sections were analyzed using an Axio Observer Z1 
fluorescent microscope (Zeiss, Thornwood, NY, USA) with StereoInvestigator® 
(MicroBrightField, Inc., Williston, VT, USA). 
 
Immunocytochemistry  
Tissue sections were incubated in 5% normal goat serum (Vector Labs, Burlingame, CA, 
USA) and 0.03% Triton X-100 (Sigma-Aldrich) in PBS for 1 h followed by the primary 
antibody for 2 h at room temperature and then overnight at 4 °C. Rabbit polyclonal 
antibodies against glial-fibrillary acidic protein (GFAP) were used to detect astrocytes 
(1:200; Dako North America, Inc., Carpinteria, CA). Mouse monoclonal antibodies against 
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ED1 were used to detect macrophages (1:100; Millipore, Temecula, CA). BMSCs in vitro on 
8-chamber culture slides (BD Falcon, Franklin Lakes, NJ; see also below) were fixed with 4 
% paraformaldehyde in PBS for 10 min and stained with monoclonal antibodies against 
caspase 3 (rabbit, clone D3E9) to detect apoptotic cells (1:100; Millipore) and 8-Oxo-2’-
deoxyguanosine (8-oxo-dG; mouse, clone 483.15) to detect cells with DNA damage (1:200; 
Millipore). After washing twice in PBS for 20 min, sections or cells were incubated with 
goat-anti-rabbit and goat anti-mouse Alexa Fluor 594 (1:200; Life Technologies, Grand 
Island, NY, USA) for 2 h at room temperature. DAPI (0.2 μl/ml; Sigma-Aldrich) was used to 
stain nuclei. Sections were covered with glass slips in fluorescent mounting medium (Dako 
North America, Inc.) and stored at 4 °C. Sections were analyzed using an Axio Observer Z1 
fluorescent microscope (Zeiss, Thornwood, NY, USA) with StereoInvestigator® 
(MicroBrightField, Inc., Williston, VT, USA). 
 
Cell quantification  
StereoInvestigator® (MicroBrightField, Inc.) was used to determine the numbers of GFP-
positive BMSCs in the injury site
15,43
 at seven days post-transplantation (n = 6/group) in 
every twelfth section and the numbers of caspase 3- and 8-oxo-dG-positive BMSCs in 
cultures (see below). All assessments were done by personnel blinded to the treatment 
groups. For GFP-positive BMSCs in the contusion, sections were 240 μm apart spanning 
the width of the spinal cord. In every section the area containing GFP-positive cells was 
outlined manually at 2.5 X magnification and covered with a 250 x 250 μm grid. At 60 X 
magnification with oil immersion, GFP-positive cells with a discernible DAPI-stained 
nucleus were marked using the optical fractionator with a 60 x 60 μm counting 
frame
7,15,43
. The numbers of immunostained cells in cultures were similarly determined. 
The numbers of GFP-positive cells were expressed as a percentage of the number of 
transplanted cells (± SEM). The numbers of caspase 3- and 8-oxo-dG-positive cells were 
expressed as a percentage of the number of seeded cells (± SEM). The numbers were 
averaged per experimental group. Image J Software was used to determine the number of 
ED1-immunoreactive macrophages in the injury site at one and four weeks post-
112 
transplantation in every twelfth section by persons blinded to the treatment groups
16
. 
Numbers were averaged per experimental group. 
 
Measurement of nervous tissue sparing 
Cresyl violet-stained sections of rats that survived for four weeks post-injection were used 
to determine the volume of spared tissue in the damaged spinal cord segment using the 
Cavalieri estimator function of StereoInvestigator® (MicroBrightField, Inc.)
7,43
. Analysis was 
performed by personnel blinded to the experimental groups (n = 6/group). The Gundersen 
Coefficient of Error was < 0.05 for all measurements. Spared tissue volume was expressed 
as a percentage of the volume (± SEM) of an equally-sized comparable uninjured spinal 




In vitro assessment of the protective effect of ESHU 
To assess ESHU’s cell protective ability we kept BMSCs in vitro under oxidative stress, 
which is known to contribute to intraneural cell transplant loss
23,24
. A total of 4x105 cells 
were incubated in 100 μl ESHU or PBS with 200 μM hydrogen peroxide (H2O2; Sigma-
Aldrich) for 24 h at 37°C. Then, 100 μl Trypan Blue (Sigma-Aldrich) was added and viable 
(Trypan Blue-negative) cells were quantified in a hematocytometer and expressed as a 
percentage of all counted cells. Results from nine samples from three independent 
experiments were averaged. In nine samples from three independent experiments, the 
average number of BMSCs expressing caspase 3, a marker for apoptosis, and 8-Oxo-2’-
deoxyguanosine (8-oxo-dG), a marker for DNA damage, were determined (see above). 
Details on caspase 3 and 8-oxo-dG staining are described in 2.8. Immunocytochemistry. 
 
Quantification of ESHU’s antioxidant ability 
ESHU’s ability to scavenge H2O2 relative to PBS was measured using a H2O2 
quantification kit (National Diagnostics, Atlanta, GA, USA) which colorimetrically measures 
Xylenol Orange-Ferric iron complex resulting from H2O2-mediated oxidation of ferrous 
iron. The linear standard curve of this assay is 15-100 ng/ml. We added 30 ng/ml H2O2 
(Sigma-Aldrich) to ESHU or PBS which was kept in reagent buffer for 30 min following the 
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manufacture’s guidelines. Absorbance was measured (Victor 2V 1420; Perkin-Elmer, 
Waltham, MA, USA) and the values from three independent experiments were averaged.  
 
Statistical analysis  
Two-tailed Student’s T-test was used to determine differences in cell numbers in vivo and 
in vitro and in H2O2 concentrations in vitro. One-way ANOVA with Tukey’s post-hoc test 
was used to assess differences in macrophages and nervous tissue sparing. Repeated 
measures ANOVA with Tukey’s post hoc test determined differences in functional 
performances. Differences between groups were considered significant when p < 0.05. 
 
RESULTS 
BMSC transplant survival 
We investigated whether ESHU protects transplanted BMSCs from death in damaged 
nervous tissue using a spinal cord contusion model. At 15 min post-injection, rounded 
BMSCs were present in the injury when mixed in either ESHU (Fig. 2a) or PBS (Fig. 2b). One 
week post-injection, in both groups many spindle-shaped cells were also found (Figs. 2c, 
2d). At 4 and 6 weeks, hardly any cells could be found in or near the contusion site after 
injection of BMSCs in ESHU (Fig. 2e) or in PBS (Fig. 2f). The temporal morphological profile 
of the grafted cells is in accordance with earlier observations
15
. Also, GFAP staining (Figs. 
2a-f) was similar as previously described
7,15
. We found that 73 ± 17 % (SEM; n =6) of 
transplanted cells had survived in ESHU while 21 ± 8 % (SEM; n = 6) survived in PBS (Fig. 
2g), which represents a significant (p < 0.05) 3.5-fold increase in survival in ESHU 
compared with PBS. At four weeks post-injection, in both groups < 1 % of the cells has 
survived in the injury site. The data show that ESHU does not affect BMSC transplant 
morphology and protects against early death resulting in increased transplant presence at 





Fig. 1. Schematic representations of transplant preparation and ESHU. (a) Isolation and transduction of bone 
marrow stromal cells. Plastic-adherent cells from femurs of adult Sprague-Dawley rats were collected, lentivirally 
transduced with green fluorescent protein, and passaged four times before used for transplantation. (a’) Green 
fluorescent protein-expressing bone marrow stromal cells in culture. Smaller panels show examples of cultured 
BMSC morphologies. (b) Structural formula of ESHU with the urethane bond in gray box. Bar = 50 µm in a’ and 25 





Fig. 2. ESHU improves the survival of bone marrow stromal cell transplants in a spinal cord contusion. Fifteen 
minutes after injection, transplanted cells (green) occupies most of the contusion regardless whether they were 
suspended in ESHU (a) or phosphate-buffered saline (PBS) (b). Staining for glial-fibrillary acidic protein (GFAP, 
red) was used to outline the contusion. Transplanted cells were mostly rounded in ESHU (insert panel a) and PBS 
(insert panel b). One week after injection, the transplant occupies only part of the contusion site but more so 
when suspended in ESHU (c) than PBS (d). The transplanted cells at this time point were mostly elongated with 
bipolar morphologies in ESHU (insert panel c) and PBS (insert panel d). Four weeks after injection, hardly any 
cells were detected in the contusion when injected with ESHU (e) or PBS (f). Similar results were observed after 
six weeks (not shown). (g) More transplanted cells survive in the contusion site the first week after injection 
when suspended in ESHU than PBS. Survival rate was measured against total number of injected cells. Error bars 
in bar graph display standard error of the mean (SEM). Asterisk = p < 0.05. Bar in a = 350 µm in a-d and 30 µm in 
inserts. 
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Effect of BMSC transplant survival on neuroprotection  
Because BMSC transplant survival is associated with neuroprotection
15
 we assessed 
whether ESHU-promoted transplant survival rendered enhanced tissue sparing (Fig. 3a-d). 
The results demonstrated that the volume of spared tissue in rats with the transplant in 
ESHU is 66 % larger (p < 0.05; n = 6/group) than in rats with the transplant in PBS at four 
weeks post-transplantation (Fig. 3e). ESHU only had no effect on spared tissue volume in 
the damaged area (Fig. 3e). The data suggest that increased survival of intraneural BMSC 
transplants early after injection enhances neuroprotection of nervous tissue. 
 
Effect of BMSC transplant survival on motor recovery  
After spinal cord contusion, motor performance depends in part on the amount of 
nervous tissue at the injury site
7
. We examined whether augmented neuroprotection by 
BMSC transplants with ESHU-enhanced survival affected motor function recovery. We 
found that rats with the transplant in ESHU performed significantly (p<0.05; n = 10/group) 
better in overground walking than rats with BMSC in PBS at 4-6 weeks post-injury (Fig. 4a). 
Rats with BMSC in ESHU performed better than rats with ESHU or PBS alone at 1-6 weeks 
post-injury and rats with BMSCs in PBS walked better overground than rats with ESHU or 
PBS alone only at 1-3 weeks post-injury (Fig. 4a). At 6 weeks, rats with BMSCs in ESHU 
showed consistent (>95%) weight-supported plantar steps with frontlimb-hindlimb 
coordination. The control transplanted rats were less consistent (50-95%) making such 
steps, whereas rats with ESHU or PBS only were less consistent and lacked frontlimb-
hindlimb coordination. During the 4th-6th week after injection, overground walking was 
increased by 1.7 ± 0.4 points on the BBB scale in rats with the transplant in ESHU which 
was significantly (p < 0.05; n = 10/group) higher than the increase in the other groups (Fig. 
4b). Higher motor functions of the hindlimbs were significantly improved (p < 0.05; n = 
10/group) by 74% in rats with BMSC in ESHU compared with BMSCs in PBS at 6 weeks 
post-injury (Fig. 4c). Sensorimotor function was significantly increased (p < 0.05; n = 
10/group) in rats with the transplant in ESHU compared with the other three groups at 6  
weeks post-injury (Fig. 4d). Rats receiving the transplant in PBS had significantly improved 




Fig. 3. ESHU augments neuroprotection by bone marrow stromal cell transplants in the contused spinal cord. 
Damage and loss of nervous tissue was observed at four weeks after a bone marrow stromal cell (BMSC) 
transplant in ESHU (a) or PBS (b) or ESHU (c) or PBS (d) alone into the contused spinal cord. (e) Spared tissue 
volume was larger with the transplant in ESHU compared with all other groups. Error bars in bar graph display 
standard error of the mean (SEM). Asterisks = p < 0.05. Bar in a = 600 µm in a-d. 
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Fig. 4. ESHU leads to enhancement of motor function recovery by a bone marrow stromal cell transplant in the 
contused spinal cord. (a) Overground walking ability was significantly improved in rats with a bone marrow 
stromal cell (BMSC) transplant in ESHU compared with BMSC in PBS at 4-6 weeks post-injury. Rats with BMSC in 
ESHU performed better than rats with ESHU or PBS alone at 1-6 weeks post-injury. Rats with BMSCs in PBS 
walked better overground than rats with ESHU or PBS alone only at 1-3 weeks post-injury. (b) Improvement in 
overground walking ability during the 4th-6th week post-injury was significantly improved in rats with a 
transplant in ESHU compared with all other groups. (c) Improved higher motor functions in rats with BMSCs in 
ESHU compared with PBS at 6 weeks post-injury. (d) Improved sensorimotor recovery in rats with the transplant 
in ESHU over all other groups and in rats with BMSCs in PBS over the control groups without BMSCs at 6 weeks 
post-injury. Error bars in bar graph display standard error of the mean (SEM). Asterisk = p < 0.05. Number sign = 
p < 0.05. 
 
Inflammatory response  
Macrophages invade damaged nervous tissue and contribute to cell death
19
. ESHU 
breakdown products could carry negative charges and so affect macrophage presence
44
. 
We tested the possible influence of macrophages on ESHU’s protective capacity by 
assessing their presence in the injury after injection of BMSCs in ESHU (Fig. 5a-c) or PBS 
(Fig. 5d-f), or ESHU or PBS only. The results demonstrated similar macrophage presence 
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Fig. 5. ESHU does not affect the injury-induced macrophage response. Macrophages (ED-1+, red) were found in 
the contusion with transplanted bone marrow stromal cell (green) in ESHU (a-c) or PBS (d-f). (g) ESHU as a 
transplant matrix or alone did not affect the presence of macrophages in the contusion at one and four weeks 
after transplantation. Error bars in bar graphs display standard error of the mean (SEM). Bar in a = 15 µm in a-f. 
 
between all groups at one (Fig. 5g) and four (Fig. 5h) weeks post-injection, suggesting that 
ESHU is non-immunogenic. The data indicate that macrophages are not implicated in 
ESHU-mediated transplant survival. 
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Oxidative stress-mediated cell death in vitro 
We tested whether ESHU protects BMSCs from H2O2-mediated death in vitro (Fig. 6a) and 
found that survival was increased four-fold in ESHU (62 ± 6%, SEM; n = 9) compared with 
PBS (15 ± 2%, p < 0.05, n = 9; Fig. 6b). ESHU resulted in an almost two-fold decrease in 
BMSCs positive for caspase 3 or 8-oxo-dG (p < 0.05, n = 9; Fig. 6c). To explore ESHU’s cell 
protective effect we assessed its proficiency in scavenging H2O2. We found that ESHU 
decreased the amount of H2O2 by 10 % (3 ng/ml) in 30 min compared with PBS (p < 0.05, 
n = 9; Fig. 6d), suggesting ESHU-mediated oxidation of H2O2. The data show that ESHU 
scavenges H2O2 and protects against oxidative stress-mediated cell death. 
 
 
Fig. 6. ESHU protects bone marrow stromal cells in suspension and scavenges hydrogen peroxide in vitro. (a) 
Schematic representation of in vitro assay of ESHU’s ability to protect bone marrow stromal cells from hydrogen 
peroxide (H2O2)-induced death. (b) Cell survival from H2O2-induced oxidative stress is better in ESHU than 
phosphate-buffered saline (PBS). (c) Fewer BMSCs positive for caspase 3 and 8-oxo-dG with ESHU (blue) than 
with PBS (orange). (d) ESHU scavenges H2O2 in PBS. Error bars in bar graphs display standard error of the mean 
(SEM). Asterisks = p < 0.05. 
121 
DISCUSSION 
We show that ESHU, a synthetic injectable reverse thermal gel, protects transplanted 
BMSCs from death thereby prolonging their presence in damaged nervous tissue and 
leading to enhanced tissue sparing accompanied by improved motor function recovery. 
Our study demonstrates that improved intraneural BMSC transplant survival enhances 
their effects on repair, which may have widespread impact on BMSC-based therapies for 
tissue repair. 
 
The inclusion of ESHU enhanced BMSC presence in a contusion in the adult rat spinal cord. 
This effect was transient possibly due to degradation of ESHU
25
. When mixed in culture 
medium, BMSC presence was significantly lower in the contusion site
15-18,47
. Possibly ESHU 
retains BMSCs better in the contusion (i.e., the site of injection) compared with culture 
medium, resulting in the higher numbers. Previously we showed that about 2.4% of GFP-
expressing BMSCs in culture medium leaked or migrated away from a contusion
15
. 
Therefore, the present results suggest that ESHU protects transplants in the contused 





The ESHU-mediated increase in BMSC survival in the contused spinal cord resulted in 
anatomical (tissue sparing) and functional (motor/sensorimotor) improvements. Spared 
tissue volume was not affected by ESHU alone, indicating that the neuroprotection was 
elicited by the increased survival of the transplant. Previously, we showed that the 
neuroprotective effects of BMSC transplants are greatest during the first week post-
injury
15
. The current finding demonstrates that the efficacy of an intraspinal BMSC 
transplant to elicit neuroprotection depends on its degree of survival and that increased 
survival leads to increased spared tissue volumes.  Neuroprotection by intraneural BMSC 
transplants is thought to result from paracrine effects
11-14
. Our finding that increased 
transplant survival results in increased tissue sparing may imply that the magnitude of 
neuroprotection elicited by the transplants depends on the concentration and/or 
availability of secreted growth factors mediating paracrine actions.  
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Overground walking and higher motor and sensorimotor functions of the paralyzed 
hindlimbs were further improved in rats that received BMSCs in ESHU. The improvements 
in overground walking were particularly evident during the second half of the 6-week 
period. It was demonstrated that BMSC transplant-mediated improvements in motor 




 injury are correlated with the 
amount of spared nervous tissue
7,53
. Thus, in our study, neuroprotection elicited by BMSC 
transplants with ESHU-increased survival likely contributes to the observed improved 
motor function recovery. At present the anatomical correlates underlying improved motor 
recovery are not completely known but may involve increased numbers of descending 
axons conducting the actual motor activity
7
 and/or increased myelination providing better 
signal conduction
53,54
, which both could result from neuroprotection.  
 
In search of potential mechanisms underlying ESHU-mediated BMSC protection, we 
assessed macrophage presence in the contusion. Macrophages are naturally present in 
damaged nervous tissue and contribute to the death of neural and transplanted 
cells
16,17,19
. Oxidation of ESHU could lead to carboxylates whose negative charges might 
inhibit adhesion of macrophages
44
 thereby limiting their contribution to cell death. We 
found that the number of macrophages in the contusion was similar with or without the 
presence of ESHU. BMSCs are hypoimmunogenic, lacking MHC class II and co-stimulatory 
molecules for effector T cell induction
48
, and suppress T cell proliferation
49
; thus the 
adaptive immune response is unlikely to be largely involved in allogeneic BMSC death. Our 
data suggest that the protective effects of ESHU result from direct effects on the 
transplant rather than indirect effects involving macrophages.   
 
Another possible mechanism underlying ESHU-promoted BMSC survival is antioxidation. 
Reactive oxygen species (ROS) accumulate rapidly in damaged nervous tissue and induce 
oxidative stress leading to cell death
20-24
. We used H2O2 to determine whether ESHU has 
the ability to scavenge ROS and thus mediate antioxidant effects. H2O2 is amply present in 
damaged nervous tissue
45
. We found that a 16 % ESHU solution removed 3 ng H2O2 in a 
30 min time period. Assuming continuous activity at 3 ng/30 min, ESHU removed ~ 20% of 
123 
added H2O2 in our in vitro assay of ESHU’s ability to protect BMSCs, which elicited a 47 % 
increase in their survival relative to PBS. The ability to scavenge ROS may be exerted 
through its urethane groups
28,29
. Possibly ESHU’s antioxidant effects may be increased 
with higher concentrations
46
. Our observations point at antioxidation as a potential 
mechanism of ESHU-promoted BMSC transplant survival. ROS are known to contribute to 
transplanted cell death
23,24
. Future studies need to define molecular factors in ESHU’s 




We demonstrate that the reparative effects of a BMSC transplant are enhanced by 
promoting their survival. This finding critically impacts current and future BMSC-based 
therapies for the central nervous system. ESHU’s ability to gel at body temperature allows 
for injection (i.e., minimally invasive) into closed injuries. Besides reducing oxidative stress 
and serving as a matrix for cells, ESHU can also be used to deliver drugs and/or 
functionalized with bioactive molecules to affect targeted biological events. These 
benefits render ESHU an important candidate in future therapies for the traumatized or 
degenerated nervous system. Furthermore, because oxidative stress is part of many 
diseases where BMSCs can be effective, such as cardiac myopathy and peripheral arterial 
disease, ESHU may have wide therapeutic relevance.   
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Discussion and Concluding Remarks 
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Spinal cord injuries result in permanent anatomical and functional damage which are so 
far untreatable. The present thesis aimed to enhance our understanding of BMSC therapy 
for spinal cord injury and to investigate approaches to increase the therapeutic efficacy of 
BMSC transplants for spinal cord repair. Using an adult rat model of spinal cord contusion, 
which is clinically the most relevant type of spinal cord injury, the efficacy of BMSCs to 
repair the contused spinal cord was studied. The results confirmed and further expanded 
previous data demonstrating that a BMSC transplant results in neuroprotection (i.e., tissue 
sparing) and improved motor, sensorimotor, ands sensory function recovery. Most 
functional improvements were strongly correlated with the neuroprotective effects, which 
included sparing of descending raphespinal axons from the brainstem. Moreover, 
increased blood vessel density at the injury epicenter was identified as a potential 
mediator of BMSC-mediated tissue sparing. Although BDNF was not found to be a 
necessary factor in BMSC-mediated tissue sparing, genetically modifying BMSCs to 
hypersecrete BDNF were found to further increase the neuroprotective effects. 
Importantly, increasing BMSC transplant survival using ESHU, a reverse thermal gel with 
anti-oxidant abilities, was found to augment the effects of a BMSC transplant on 
anatomical and functional repair of the contused spinal cord. 
 
PARACRINE FUNCTIONS OF BMSCs 
The efficacy of BMSCs is thought to be due to the paracrine actions of secreted factors. 
BSMCs secrete a variety of growth factors and cytokines that can be grouped into three 
repair-promoting categories. The first group is comprised of factors that affects blood 
vessels. Among these factors are vascular endothelial growth factor (VEGF), hepatocyte 
growth factor (HGF) and angiopoietin-1 (ANG-1).
1,2
 We found increased blood vessel 
density at a contusion site after BMSC transplantation (Chapter 2) suggesting that BMSC-
mediated angiogenesis is involved in its neuroprotective actions. Further studies need to 
elucidate which of the abovementioned BMSC-derived factors play a role in the formation, 
repair, or sparing of blood vessels near an injury site. One possible mechanism by which 
BMSC transplants may elicit vascular repair is by secretion of Ang-1 which is known to 
stabilize blood vessels thereby decreasing their permeability.  
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The second group consists of factors that affect cell survival. This group includes BDNF, 
glial-derived neurotrophic factor (GDNF), nerve growth factor (NGF) and ß-fibroblast 
growth factor (ß-FGF).
3,4
 We found that BDNF is not a necessary factor for BMSC-mediated 
neuroprotection but the therapeutic efficacy of BMSC transplants can be enhanced using 
BDNF-hypersecreting BMSCs (Chapter 3). A specific repair-related event may be affected 
by many different trophic factors as was confirmed in Chapter 3. Conversely, a particular 
trophic factor may affect multiple events. It is important to acquire thorough 
understanding of the role(s) of a particular repair-supporting factor, including the benefits 
and detriments, before approaches can be developed to enhance BMSC-based spinal cord 
repair.  
 
The third group of repair-supporting factors secreted by BMSC affect the immune 
response. This group includes interleukin-10 (IL-10) and transforming growth factor ß-1 
(TGF-ß1). The inflammatory response plays a dual role in spinal cord injury. After the initial 
impact, a massive influx and proliferation of macrophages is evident. These macrophages 
are needed to clear cellular debris and reorganize tissue at the injury site. In doing so, they 
secrete molecules that increase oxidative stress and exacerbate secondary tissue 
degeneration. Currently, the differential role of M1 macrophages, with mainly 
deteriorating effects, and M2 macrophages, with predominantly beneficial effects, are 
being investigated. Within the setting of this complex inflammatory response, the role of 
immune modulatory factors secreted by BMSCs remains to be elucidated. 
 
FACTORS DETERMING OUTCOME 
Interestingly, investigations of BMSC transplants in spinal cord injury have led to different 
and at times conflicting conclusions. Many groups, but not all, have reported anatomical 
or functional improvements after BMSC transplantation in the injured spinal cord. Some 
groups report BMSC-mediated effects on axonal regeneration in the injured spinal cord. 
Many different aspects can influence the effects of BMSCs on repair in models of spinal 
cord injury. Firstly, the age of BMSCs affects their genetic expression profile, including 
expression of genes involved in neural repair. Previously, we characterized the gene 
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expression profiles of BMSCs that were passaged three (P3) or fourteen (P14) times and 
revealed a decrease in plasticity and repair aptitude of long-term cultured BMSCs .
5
 In 
addition, the age of the rat from which the BMSCs are harvested affect BMSC plasticity 
and their proliferative life span. BMSCs from younger rats have higher telomerase activity 
and higher expression of Sox-2 and Nanog, increasing their proliferative life span and cell 
plasticity, respectively.
6.7
 Also, human bone marrow stromal cells exhibit donor variations 
in secretion patterns of growth factors and cytokines, affecting axons growth and 
functional recovery in rat spinal cord injury.
8
 Clearly, determination and standardization of 
the optimal BMSC age and donor lot is necessary to validly compare studies and move 
forward with BMSC therapy research. 
 
Another major factor determining outcome after BMSC transplantation is the model 
system used. The strain and gender of the rats used affect the immune response to the 
transplanted BMSCs. In the present thesis, female rats were used because their short 
urethra makes manual bladder expression more practical, and their more gentile 
temperament makes handling easier. Sprague Dawley rats were used, which is an outbred 
strain, resulting in greater surgery survival rates and less complications. Allogeneic 
transplantations in Sprague Dawley rats could possibly result in different immune 
responses than using more inbred strains, thus allowing for more syngeneic 
transplantations. Different injury devices, injury types and injury levels used result in 
different baseline functional deficits. Future research needs to determine which types of 
injury model best predicts functional recovery in humans, and the site, dose and timing of 
BMSC injection influence cell survival and cell dynamics. Differences in any of these factors 
can impact the observed outcome. A golden standard model system for testing cellular 
transplants for spinal cord injury does not exist and further research is needed to 
determine the true therapeutic efficacy of BMSCs. On the other hand, there is a high 
degree of variation between humans and having differences between models of spinal 
cord injury may in fact support our understanding of the potential of BMSC-based spinal 
cord repair.  
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Although the rat contusion model of spinal cord injury shows considerable anatomical 
similarities to human spinal cord injury, and is generally considered to be a suitable model 
system, there are limitations that affect the interpretation of the repair effects of BMSCs, 
especially in light of their potential for human spinal cord repair. Firstly, rats show some 
degree of functional recovery even in the complete absence of supraspinal input, likely 
due to the presence of a locomotor central pattern generator (CPG) in the lumbar spinal 
cord segments. Within days after injury, rats will start to show hindlimb joint movements, 
followed by stepping movements, and, depending on the severity of the injury, weight 
supported stepping. Reorganization of the CPG is believed to underlie this functional 
recovery. Humans do not seem to reorganize their lumbar spinal neurons in a way that 
leads to functional recovery, even though a lumbar CPG is present. Rats are quadrupeds 
and following awakening from anesthesia after a spinal cord injury, they begin to move 
around using their forelimbs while dragging their hind limbs. This constant sensory input 
to the hind limbs is believed to positively affect functional recovery. Indeed, a recent study 
shows that hind limb immobilization and hind limb stretching therapy in rats hinders the 
functional recovery of spinal cord injured rats.
9
 Treatments tested in rats that improve 
functional repair, might do so by positively affecting spinal cord reorganization below the 
level of injury. Humans might be more dependent on supraspinal input for effective 
functional recovery. The widely used BBB locomotor recovery scale used in rats, also used 
in this thesis, may not adequately reflect these differences. In the 21-point BBB scale small 
changes in tissue can be correlated to changes on the scale. In humans, no scale exists in 
which the extent of tissue damage/sparing can be correlated with a functional rating 
scale. Although it seems plausible that neuroprotective interventions that are so closely 
correlated to functional recovery in rats would also be beneficial for humans, no such 
evidence exists to date. 
 
Understanding the factors underlying the observed differences in recovery between rats 
and humans as well as gaining insight in the mechanisms of action of proposed treatments 
will help us predict which (combination of) therapies may restore function in humans. 
Conversily, data from the few spinal cord injured patients injected with cellular transplants 
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so far, both from the discontinued Geron trial, as well as from the ongoing StemCell trial 
may provide us with insights regarding the questions we need to focus on in the 
laboratory. However, caution is warranted when efforts to translate therapies into the 
clinic are taken too prematurely, since lack of efficacy in unfully understood treatments, 
might unduely discourage patients, the scientific community as well as funding agencies, 
and decrease the progress of basic research. 
 
COMBINATION STRATEGIES 
Clearly, BMSCs or any stem cell by itself will not provide the ‘silver bullet’ for restoring 
functional repair after spinal cord injury. The neuroprotective properties of these cells will 
have to be combined with regenerative and rehabilitative strategies to regain function 
after paralysis. One recent study showing the additive strength of combination strategies 
was by Van Den Brand et al
10
. Monoamine agonist, epidural electrical stimulation and 
neurorehabilitation within a robotic harness were successfully combined to considerably 
improve walking after spinal cord injury in a rat model. 
 
CONCLUSION 
BMSC transplantation is a promising cell-based strategy to promote repair of the injured 
spinal cord. The knowledge we gain from studying BMSC transplants within spinal cord 
injury models, provide valuable insights into cell-based treatments for central nervous 
system disorders that can one day be translated into the clinic providing treatments to 
improve the quality of life of spinal cord injured patients.  
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A spinal cord injury leads to loss of neural cells and interruption of axonal tracts, resulting 
in partial or complete motor, sensory, and autonomous dysfunction below the level of 
injury. The most prevalent causes of traumatic spinal cord injuries include traffic 
accidents, sport injuries, and violence. Non-traumatic causes include tumor compression 
and infections. The initial impact results in immediate death of neurons and glial cells, and 
damage to axons and blood vessels. The impact further sets off a series of 
pathophysiological events causing progressive secondary damage which continues for 
days to months. Contributing events to secondary damage are inflammatory cells and 
release of cytotoxic molecules. The presence of growth-inhibitory molecules in scar tissue 
at the injury site and the gradual formation of a fluid-filled cyst contribute to a hostile 
environment for repair-supporting events including axonal regeneration. Currently, there 
is no therapy available that effectively restores the damaged axonal tracts, so that most 
people with spinal cord injury suffer permanent paralysis. 
 
STEM CELL THERAPY  
Chapter 1 provides a general introduction on stem cells for repair of the central nervous 
system. Different types of stem cells can be used for repair of the central nervous system; 
each type with its specific advantages and disadvantages. Embryonic and fetal stem cells 
have the advantage of the potential to differentiate into almost any cell type and can 
potentially replace damaged and lost cells in the nervous system. Disadvantages of these 
cells include ethical considerations regarding cell harvest and the risk of tumor formation 
as a result of uninhibited proliferation. Adult stem cells are less tumorigenic but also have 
less differentiation capacity. Stem cells can exert their beneficial effect by secreting 
growth factors with protective and/or proliferative effects on neural tissue. One easy to 
harvest adult stem cell is the bone marrow-derived mesenchymal stem cell, also called 
bone marrow stromal cell (BMSC). Part two of the introduction specifically focuses on 
these BMSCs as a therapy for spinal cord repair. BMSCs are relatively easy to harvest from 
adult bone marrow and can be cultured quickly in defined growth medium. They secrete 
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various growth factors which include neurotrophic factors and have a protective effect on 
neural tissue after transplantation into the injured adult rat spinal cord. This thesis has 
two main goals: (1) to expand the our knowledge of BMSC therapy for spinal cord repair, 
and (2) to investigate approaches to enhance the therapeutic efficacy of intraspinal BMSC 
transplants. The experiments in this thesis are conducted using an adult rat model of 
spinal cord injury involving a T9 laminectomy and subsequent contusion of the exposed 
spinal cord using an automated impactor which results in hindlimb and tail paralysis. 
Anatomically, the impact results in loss of neurons and glia cells, damage to axons and 
blood vessel, and an influx of inflammatory cells which contribute to progressive 
secondary tissue loss. This model mimics the consequences of spinal cord injury in 
humans.  
 
BMSC-MEDIATED NEUROPROTECTION AND REPAIR  
Chapter 2 examined whether BMSC-mediated neuroprotection enhances motor and 
sensory function recovery after transplantation into an adult rat model of spinal cord 
contusion. The relationship between BMSC-mediated tissue sparing and different aspects 
of functional recovery were investigated. The results showed that BMSC transplantation 
positively affects different parameters for (sensori)motor function (BBB subscore, foot 
print analysis, horizontal ladder walking) and sensation (thermal hyperalgesia and 
mechanical allodynia) and that these effects are correlated with the volume of spared 
nervous tissue in the contused segment. In addition, we found that the BMSC-
transplanted segment contained more blood vessels than control (not-transplanted) rats, 
which may contribute to the increased volumes of spared tissue. We also found that rats 
with BMSCs contained more axons originating from the raphe nuclei in the brain stem, 
which may contribute to the observed improvements in motor recovery.  
 
DE ROLE OF BDNF IN BMSC-MEDIATED NEUROPROTECTION 
In chapter 3 we studied the role of BDNF, one of the growth factors secreted by BMSCs, in 
BMSC-mediated neuroprotection by increasing and decreasing the expression of BDNF in 
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BMSCs through lentiviral transduction. In vitro, BDNF was shown not to be a necessary 
factor for the observed protective effect on spinal motoneurons. BMSCs with silenced 
BDNF production had a similar beneficial effect on neural survival as control BMSCs, 
possibly due to compensatory effects of other secreted trophic factors. BMSCs 
overexpressing BDNF resulted in an increase in motoneuron survival that was not seen 
with control BMSCs or with BMSCs with silenced BDNF production. In vivo, this beneficial 
effect of BDNF-overexpressing BMSCs was confirmed; more motoneurons survived in the 
spinal cord after transplantation of BDNF-hypersecreting BMSCs, compared to unmodified 
BMSCs or BMSCs with silenced BDNF production. Rats that received BDNF-hypersecreting 
BMSCs were found to have a higher density of grey matter blood vessels, which could 
have been a mediating factor in the improved motoneuron survival. In addition, we found 
BDNF to be a necessary factor for BMSC survival in vivo. BMSCs with silenced BDNF 
production did not survive the first week of transplantation, which may explain the lack of 
tissue sparing in these rats. 
 
BMSC SURVIVAL 
Survival of BMSCs in the damaged spinal cord is poor and limits their repair efficacy. One 
week after transplantation, about twenty percent of the transplanted cells survive. 
Different factors contribute to this poor BMSC survival, including phagocytosis by 
macrophages, lack of oxygen and nutrients by ruptured blood vessels, and the presence of 
reactive oxygen species and other cytotoxic molecules at the injury site. In chapter 4 we 
investigated whether BMSC survival could be improved by suppressing the inflammatory 
response. Three clinically used anti-inflammatory drugs, Minocycline, Methylprednisolone, 
and Cyclosporine were tested for their ability to suppress the number of activated 
macrophages in the injured spinal cord and thereby increase BMSC survival. All three 
drugs were effective in decreasing the macrophage response, but this did not improve 
transplanted BMSC survival. 
 
In Chapter 5 we investigated whether BMSC survival could be improved by transplanting 
the cells in the reverse thermal gel, poly(ethylene glycol) -poly(serinol hexamethylene 
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urethane), or ESHU, which has anti-oxidative properties. We showed that BMSCs survived 
the first week of transplantation better when transplanted in ESHU and that this improved 
survival was associated with increased tissue sparing and improved motor and 
sensorimotor function recovery. A likely contributor to the improved BMSC survival is the 
anti-oxidative ability of the poly-urethane group of ESHU. This antioxidant effect was 
confirmed in vitro.  
 
CONCLUSION 
BSMC transplantation has beneficial anatomical effects associated with improved motor, 
sensorimotor, and sensory function recovery in a rat model of spinal cord contusion.  
Some of these effects can be further enhanced by overexpressing BDNF in the 
transplanted BMSCs. Short term BMSC survival can be improved by transplanting the cells 
in ESHU and this leads to increased tissue sparing and functional improvement, indicating 
that survival is a determinant in the therapeutic efficacy of BMSC transplants. Future 
research will need to focus on combinations of neuroprotective BMSC transplants with 
axonal regenerating promoting therapies to further optimize BMSC-based therapy for 














Een dwarslaesie leidt tot verlies van zenuwcellen en een onderbreking van   zenuwbanen 
in het ruggenmerg, leidend tot gedeeltelijke of volledige verlamming, gevoelsverlies en 
autonome functiestoornissen onder het niveau van het letsel. Tot de meest voorkomende 
oorzaken van traumatische dwarslaesies behoren verkeersongelukken,  sportongevallen 
en geweld. Niet-traumatische oorzaken zijn onder andere tumorcompressie en infecties. 
De initiele impact leidt tot direct verlies van neuronen en gliacellen en schade aan axonen 
enz bloedvaten. De impact zet vervolgens een pathofysiologische cascade op gang die nog 
dagen tot maanden tot secundaire weefselschade kan leiden, onder andere door influx 
van ontstekingscellen en vrijkomen van cytotoxische moleculen. De formatie van 
littekenweefsel en een met vocht gevulde cyste dragen bij aan een vijandig milieu waarin 
geen regeneratie van axonen plaatsvindt. Er is vooralsnog geen therapie beschikbaar die 
deze verbindingen kan herstellen, waardoor de meeste mensen met een dwarslaesie 
moeten leven met permanente verlamming. 
 
STAMCELTHERAPIE 
In hoofdstuk 1 wordt in deel 1 een algemene introductie gegeven over stamcellen voor 
herstel van het centrale zenuwstelsel (CZS). Verschillende typen stamcellen kunnen 
worden gebruikt als therapie voor CZS schade, elk met speciefieke voor-en nadelen. 
Embryonale en foetale stamcellen hebben het voordeel van mogelijkheid tot differentiatie 
tot bijna elke cel in het lichaam en daarmee de potentie om beschadigde/verloren 
zenuwcellen te vervangen. Nadelen van deze cellen zijn ethische  problemen met celoogst 
en een risico op tumorformatie door ongeremde proliferatie. Volwassen stamcellen en 
precursorcellen hebben doorgaans minder differentiatiepotentie, maar tonen 
tegelijkertijd ook minder risico op tumorvorming. De werkzaamheid van deze volwassen 
stamcellen is gelegen in de afgifte van groeifactoren die een beschermend en/ of 
proliferatief effect of neuraal weefsel hebben. Een makkelijk te oogsten type volwassen 
stamcel is de uit het beenmerg afkomstige mesenchymale stamcel, ook wel BeenMerg 
Stromale Cel (BMSC) genoemd. In deel 2 van de introductie wordt specifiek ingegaan op 
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deze BMSC’s als therapie voor het beschadige ruggenmerg. BMSC’s zijn relatief makkelijk 
te verkrijgen uit volwassen beenmerg en eenvoudig te kweken in groeimedium. Zij geven 
diverse groeihormonen af, waaronder neurotrofe factoren, en hebben na transplantatie in 
het beschadigde ruggenmerg een beschermend effect op neuraal weefsel in ratmodellen 
van dwarslaesie. Dit proefschrift heeft twee hoofddoelstellingen: (1) om onze kennis over 
BMSC therapie voor herstel van het ruggenmerg te vergroten en (2) om middelen te 
vinden om de werkzaamheid van intraspinale BMSC transplantaten te vergroten. De 
experimenten in dit proefschrift maakten gebruik van een in vivo rattenmodel, waarbij na 
laminectomie van thoracaal segment T9, met behulp van een geautomatiseerde impactor 
een contusielaesie wordt aangebracht. Dit resulteert in paralyse van achterpoten en 
staart. Histologisch leidt de impact tot schade aan neuronen, axonen, gliacellen en 
bloedvaten en tot influx van ontstekingscellen, wat bijdraagt aan progressieve secundaire 
weefselschade. Dit model bootst de consequenties van ruggenmergletsel in mensen na. 
 
BMSC-GEMEDIEERDE NEUROPROTECTIE EN HERSTEL 
In hoofdstuk 2 is gekeken of de door BMSC-gemedieerde neuroprotectie een positief 
effect heeft op herstel van motoriek en sensibiliteit na transplantatie in een ratmodel van 
dwarslaesie. Het verband tussen BMSC-gemedieerde weefselsparing en verschillende 
facetten van functie werd onderzocht. De resultaten toonden dat BMSC transplantatie 
een positief effect heeft op verschillende parameters voor (sensori)motoriek (BBB-
subscore, voetprintanalyse, vaardigheid op een horizontale ladder) en sensibiliteit 
(thermische hyperalgesie en mechanische allodynie) en dat deze effecten gecorreleerd 
zijn aan het gespaarde weefselvolume. Daarnaast vonden we dat BMSC-getransplanteerde 
segmenten meer bloedvaten bevatten dan controles, wat mogelijk een bijdrage heeft 
geleverd aan de grotere volumes gespaard weefsel. Ook bleek dat ratten met BMSC meer 
axonen hadden afkomstig van de raphe kernen in de herstenstam, wat mogelijk een 





DE ROL VAN BDNF IN BMSC-GEMEDIEERDE NEUROPROTECTIE 
In hoofdstuk 3 werd de rol onderzocht die Brain-derived neurotrophic factor (BDNF), een 
van de neurotrofe factoren die BMSC uitscheidt, speelt in BMSC-gemedieerde 
neuroprotectie. Hiertoe werd de expressie van BDNF in BMSC door middel van lentivirale 
factoren verlaagd en verhoogd. In vitro bleek BDNF geen noodzakelijke factor voor het 
geobserveerde beschermende effect op motoneuronen in de ventrale horn; ook BMSC 
zonder BDNF (BMSC-shRNA-BDNF) hadden een gunstig effect op neurale overleving, 
mogelijk door het compensatoire effect van andere uitgescheide groeifactoren.  Echter, 
overexpressie van BDNF (BMSC-BDNF) resulteerde wel in een geprolongeerd effect op 
motoneuron overleving dat met BMSC en BMSC-shRNA-BDNF niet werd gezien. Ook in 
vivo bleek overexpressie van BDNF voordelig; meer motoneuronen overleefden in de 
ventrale hoorn na BMSC-BDNF therapie, een effect dat met BMSC en BMSC-shRNA-BDNF 
niet werd gezien. Ook werden meer bloedvaten gevonden in de grijze stof van deze BMSC-
BDNF behandelde ratten, wat mogelijk een mediator is geweest voor de verbeterde 
motoneuron overleving. Verder bleek BDNF expressie noodzakelijk voor BMSC overleving 
in vivo. BMSC-shRNA-BDNF overleefden de eerste week na transplantatie niet, wat 
mogelijk het gebrek aan een weefselsparend effect in deze ratten verklaart. 
 
OVERLEVING BMSC 
De overleving van BMSC’s in het beschadigde ruggemerg is matig en beperkt de 
therapeutische werking. Een week na transplantie overleeft ongeveer 20% van de 
getransplanteerde cellen. Verschillende factoren dragen mogelijk bij aan deze matige 
overleving van BMSC’s, waaronder fagocytose door macrofagen, gebrek aan 
voedingsstoffen en zuurstof door gescheurde bloedvaten en de aanwezigheid van 
reactieve zuurstofverbindingen en andere toxische moleculen ter plaatse van het letsel. In 
hoofdstuk 4 werd gekeken of de overleving van BMSC’s kon worden verbeterd door 
onderdrukking van de ontstekingsreactie. Drie klinisch beschikbare ontstekingsremmers, 
Minocycline, Methylprednisolon en Cyclosporine, werden onderzocht op hun vermogen 
om het aantal macrofagen in het beschadigde ruggenmerg te onderdrukken en zodoende 
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de overleving van BMSC’s te verbeteren. Alle drie medicijnen waren effectief in het 
remmen van de macrofaagrespons, maar we detecteerden geen verbeterde overleving 
van BMSC’s. 
In hoofdstuk 5 werd onderzocht of de overleving van BMSC’s kon worden verbeterd door 
de cellen te transplanteren in de thermaal reversibele biogel poly(ethylene glycol) -
poly(serinol hexamethylene urethane), ofwel ESHU, een gel met anti-oxidatieve 
eigenschappen. BMSC’s overleefden de eerste week na transplantatie beter wanneer de 
cellen getransplanteerd werden in ESHU en deze verbeterde overleving ging gepaard met 
meer weefselsparing en verbeterd motorisch herstel. Een mogelijke verklaring voor de 
verbeterde BMSC overleving is het anti-oxidatieve effect van het poly-urethaan element 
van ESHU. Het anti-oxidatieve effect werd bevestigd in vitro. 
 
CONCLUSIE 
BMSC transplantatie heeft positieve histologische effecten, geassocieerd met verbeterd 
herstel van motorische en sensibele functies in een rattenmodel van dwarslaesie. 
Sommige van deze effecten kunnen verder verbeterd worden door upregelatie van BDNF 
in BMSC’s. Korte termijn overleving van BMSC kan verbeterd worden door de cellen te 
transplanteren in ESHU, en deze verbeterde overleving gaat gepaard met meer 
weefselsparing en functioneel herstel, wat impliceert dat celoverleving een determinant is 
voor de werkzaamheid van BMSC transplantaten. Toekomstig onderzoek zal zich moeten 
richten op het combineren van de neuroprotectieve BMSC therapie met axon 
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